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Abstract: Galectin-3 (Gal-3) regulates basic cellular functions such as cell–cell and cell–matrix
interactions, growth, proliferation, differentiation, and inflammation. It is not surprising, therefore,
that this protein is involved in the pathogenesis of many relevant human diseases, including cancer,
fibrosis, chronic inflammation and scarring affecting many different tissues. The papers published in
the literature have progressively increased in number during the last decades, testifying the great
interest given to this protein by numerous researchers involved in many different clinical contexts.
Considering the crucial role exerted by Gal-3 in many different clinical conditions, Gal-3 is emerging
as a new diagnostic, prognostic biomarker and as a new promising therapeutic target. The current
review aims to extensively examine the studies published so far on the role of Gal-3 in all the clinical
conditions and diseases, listed in alphabetical order, where it was analyzed.
Keywords: Galectin-3; Gal-3
1. Introduction
Galectins were initially isolated as β-galactoside-binding proteins. They represent a family of
widely expressed lectins in metazoans. In mammalians a total of 15 galectins have been identified so
far, containing either one or two ∼130 amino-acid-long conserved carbohydrate recognition domains
(CRD)s [1–3]. Galectins are synthesized in the cytoplasm and interact with cell surface glycans
following their secretion by a non-classical exocytic pathway (i.e., not via the ER/Golgi secretory
route), that is likely to be an exosome-mediated secretory route [4,5]. Their ability to crosslink
glycosylated ligands allows them to form a dynamic lattice. The galectin lattice regulates many
different functions such as the diffusion, compartmentalization and endocytosis of plasma membrane
glycoproteins and glycolipids, the selection, activation and arrest of T cells, receptor kinase signaling
and the functionality of membrane receptors, (including the glucagon receptor, glucose and amino
acid transporters, cadherins and integrins) [6].
Int. J. Mol. Sci. 2018, 19, 379; doi:10.3390/ijms19020379 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2018, 19, 379 2 of 59
Although the galectins are cytosolic proteins, there is abundant evidence for their secretion
from the cytosol via nonclassical pathways or translocation to the nucleus or the other cellular
compartments [4,7]. The galectin family can be subdivided into three different groups:
1. Prototypic single-CRD galectins that can form non-covalent homodimers. The following galectins
belong to this group: Gal-1, Gal-2, Gal-5, Gal-7, Gal-10, Gal-11, Gal-13, Gal-14 and Gal-15.
2. Tandem-repeats of two CRD motifs, similar but not identical, including Gal-4, Gal-6, Gal-8, Gal-9
and Gal-12.
3. The chimera-type. The only member of this group is represented by Gal-3, with a single CRD and
an intrinsically disordered sequence at the N-terminal domain that promotes oligomerization.
In addition, Gal-3 is the only one to be able to pentamerize. It exhibits specific pleiotropic
biological function, playing a key role in many physiological and pathological processes (Figure 1).
Figure 1. The structure of the galectin family members. The galectin family members are divided
into three types: The prototype with one carbohydrate recognition domain (CRD), the tandem-repeat
type with two CRDs connected by a non-conserved linker, and the chimeric type with one CRD and
a non-lectin N-terminal domain (ND). Some galectins can self-associate into dimers or oligomers.
1.1. Gal-3 Identification
Gal-3 is a member of a growing family of β-galactoside binding lectins [8], with an approximate
molecular weight of 30,000. It was originally identified in murine peritoneal macrophages and named
MAC-2 [9]. Later, it was also described as CBP-35, a 35-kDa carbohydrate-binding protein in mouse
3T3 fibroblasts [10]. Since then it was detected in numerous type of tumoral tissues [11], basophilic
leukemia cells [12], human and murine tumor cells [13,14], human lung [15] rat intestine [16] and
human HeLa cells [17].
Gal-3 is encoded by the LGALS3 Gene, which has previously been known under different
names: IgE-Binding Protein [18], MAC-2 [9], Lectin L-29 [19], L-34 [20] CBP-30 [21], Galectin
3 (Gal-3), Advanced Glycation End-Product Receptor 3, Lectin, Galactoside-Binding, Soluble,
3, Carbohydrate-Binding Protein 35 (CBP 35) [22], Galactose-Specific Lectin 3, Laminin-Binding
Protein [23], 35 KDa Lectin, Galactoside-Binding Protein, GALBP [12].
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1.2. Gal-3 Tissue Distribution
In adults, Gal-3 is ubiquitously expressed, while experiments performed in mice demonstrated
during embryogenesis its expression is tissue- and time-dependent. Although its expression is mainly
related to the epithelial cells and myeloid/amoeboid cells, Gal-3 expression was detected in many
different types of cells, including: Small intestinal epithelial cells, colonic epithelia, corneal and
conjuctival epithelia, olfactory epithelium, epithelial cells of kidney, lung, thymus, breast, and prostate.
It was also detected in ductal cells of salivary glands, pancreas, kidney, eye, in intrahepatic bile ducts,
in fibroblasts, chondrocytes and osteoblasts, osteoclasts, keratinocytes, Schwann cells and gastric
mucosa, as well as in the endothelial cells from various tissues and organs [24]. In addition, there are
numerous data on Gal-3 expression in the cells involved in immune response, such as neutrophils,
eosinophils, basophils and mast cells, Langerhans cells, dendritic cells, as well as monocytes and
macrophages from different tissues. In some other cell types, such as lymphocytes, Gal-3 is not
normally expressed, yet it expression can be induced by various stimuli [4,7]. Moreover, Gal-3
displays pathological expression in many tumors, such as those affecting the pancreas, the liver,
the colonic mucosa, the breast, the lung, the prostate, the head and neck, the nervous system and the
thyroid [24–26].
1.3. Gal-3 Protein/Gene Structure and Carbohydrate Binding
Gal-3 is the most studied member of the galectin family. It is the sole member of chimera-type
family of galectins [27]. Gal-3 (m.w. 31 kDa) is found in solution as a monomer with two functional
domains [22,28–30]. Gal-3 is so far unique in the family in having an extra long and flexible N-terminal
domain consisting of 100–150 amino acid residues, according to species of origin, made up of repetitive
sequence of nine amino acid residues rich in proline, glycine, tyrosine and glutamine and lacking
charged or large side-chain hydrophobic residues [4,7,29,30]. The N-terminal domain contains sites for
phosphorylation (Ser 6, Ser 12) [31,32] and other determinants important for the secretion of the lectin
by a novel, nonclassical mechanism [33]. The C-terminus is the CRD, consisting of about 135 amino
acid residues; this is what defines the molecule as a galectin. The structure of the LGALS3 gene is
consistent with the multi-domain organization of the protein. The gene for Gal-3 is composed of six
exons and five introns (human locus 14q21-22). Exon I encodes the major part of the 5′ untranslated
sequence mRNA. Exon II contains the remaining part of the 5′ untranslated sequence, the protein
translation initiation site and the first six amino acids including the initial methionine. The repetitive
sequence in the N-terminal half of the gene product is encoded within exon III. Exons IV, V and
VI code the C-terminal half of the protein [7,34]. Gal-3, like most members of the galectin family,
acts as a receptor for ligands containing poly-N-acetyllactosamine sequences which consist of many
disaccharide units: Gal β1,4 GlcNAc bond to each other by β1,3 linkage. However, Gal-3 appears to
have an increased affinity for the more complex oligosaccharides [4,34].
1.4. Gal-3 Subcellular Localization
Although Gal-3 is predominantly located in the cytoplasm, it has also been detected in the
nucleus, on the cell surface and in the extracellular environment, suggesting a multifunctionality of
this molecule.
Extracellular Gal-3 modulates important interactions between epithelial cells and extracellular
matrix, and plays a role in the embryonic development of collecting ducts [35]. In contrast, intracellular
Gal-3 is important for cell survival due to its ability to block the intrinsic apoptotic pathway [36,37].
In this regard, it has been demonstrated that cytoplasmic Gal-3 in cancer cells is usually associated
with an aggressive phenotype, in opposition to nuclear Gal-3 [38].
Nuclear localization of Gal-3 was first described in in vitro proliferating fibroblasts [39–41], but not
in fibroblasts with replicative deficiencies [42]. Nuclear Gal-3 is localized mainly in interchromatin
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spaces, at the border of condensed chromatin, on the dense fibrillar component, and at the periphery
of the fibrillar centers of nucleoli [43].
1.5. Gal-3 Secretion
Gal-3 is synthesized on free ribosomes in the cytoplasm and lacks any signal sequence for
translocation into the endoplasmic reticulum (ER) [4]. Although it does not traverse the endoplasmic
reticulum/Golgi network, there is abundant evidence for Gal-3 also having an extracellular location.
This protein has been shown to be secreted from cells by a novel, incompletely understood mechanism
called ectocytosis, which is independent of the classical secretory pathway through the ER and
Golgi system [4,44,45]. A short segment of the Gal-3 N-terminal sequence comprising residues 89–96
(Tyr-Pro-Ser-Ala-Pro-Gly-Ala-Tyr) has been found to play a critical role in Gal-3 secretion. However,
this sequence is not sufficient on its own to cause the direct secretion of the CAT fusion protein,
indicating that it is operative in the context of a large stretch of the N-terminal sequence of Gal-3 [33].
Immunohistochemical studies have indicated that the first step in Gal-3 secretion is its accumulation at
the cytoplasmic side of the plasma membrane [44–46].
1.6. Gal-3 Ligands
There are several known ligands for Gal-3 [47]. They can be subdivided, according to their
localization, into extracellular, intracellular and nuclear ligands.
1.6.1. Gal-3 Extracellular Ligands
Gal-3 binds to glycosylated extracellular matrix components, including laminin, fibronectin,
tenascin, chondroitin sulfate and Mac-2 binding protein [21,48–51]. Some cell-surface adhesion
molecules, such as integrins, are also ligands for Gal-3 and galectins, through binding to the
extracellular domains of one or both subunits of an integrin, may positively or negatively modulate
integrin activation, and affect binding with extracellular ligands [52].
A major ligand for Gal-3 on mouse macrophage is the α-subunit of the integrin αMβ2, otherwise
known as CD11b/18 [53,54]. Moreover, Gal-3 also interacts with integrin α1β1 via its CRD domain
in a lactose dependent manner [55]. Gal-3 also seems to be an endogenous cross-linker of the CD98
antigen, leading to the activation of integrin-mediated adhesion [53].
1.6.2. Gal-3 Intracellular Ligands
Gal-3 is also known to have an intracellular location and to interact with several proteins inside
the cell, such as: Cytokeratins [56], CBP70 [57], Chrp [58], Gemin4 [59], Alix/AIP-1 [60], and Bcl-2 [61].
It is worth noting that almost all of the mentioned intracellular ligands interact with Gal-3 via
protein–protein rather than lectin-glycoconjugate interactions. The only exception is the cytokeratins.
In fact, it has been shown that cytokeratins of MCF7, as well as other human cells, carry a novel
posttranslational modification, a glycan with a terminal α linked GalNAc and that these residues are
recognized in vitro by mammalian Gal-3 [56].
1.6.3. Gal-3 Nuclear Ligands
Nuclear Gal-3 can interact with Gemin-4, a component of a macromolecular complex containing
approximately 15 polypeptides, among them SMN (survival of motor neuron) protein, Gemin-2,
Gemin-3, some of the Sm core proteins of snRNPs and other as yet unidentified proteins.
These complexes are implicated in processes directly or indirectly related to pre-mRNA splicing.
The identification of Gemin-4 as an interacting partner of Gal-3 provides strong evidence that this
galectin can play a role in splicesome assembly in vivo [59,60]. The screening of a Jurkat cell cDNA
library, by the yeast two-hybrid method using Gal-3 as bait allowed the identification of another Gal-3
binding protein. It is a human homologue of ALG-2 linked protein x (Alix) or ALG-2 interacting
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protein-1 (AIP-1) [60]. This protein interacts with ALG-2, a calcium binding protein necessary for cell
death induced by different stimuli. AIP-1 cooperates with ALG-2 in executing the calcium dependent
requirements along the cell death pathway [62,63]. Alix/AIP-1 contains a proline, glycine, alanine and
tyrosine rich sequence in the C-terminal region, which is highly homologous to the tandem repeat
sequence in the N-terminal part of Gal-3 [60].
2. Role of Gal-3 in Different Clinical Conditions and Diseases (Listed in Alphabetical Order)
Gal-3 is a multifunctional protein engaged in different biological events, in different tissues,
playing a relevant role in many different clinical conditions and diseases. Since its discovery as an
IgE-binding protein in 1971 and subsequently its recognition as Mac-2, a 32-kDa cell surface antigen
expressed on murine peritoneal macrophages in 1982, more than 8200 papers have been published in
the literature so far (Figure 2).
Figure 2. PubMed (U.S. National Library of Medicine, Medical Institutes of Health) records on academic
publications on Gal-3, total 8289 items by December 2017. Search Strategy MESH terms: Galectin 3 or
Gal-3 or Advanced Glycation End-Product Receptor 3 or Lectin, Galactoside-Binding, Soluble, 3 or
Carbohydrate-Binding Protein 35 (CBP 35) or Galactose-Specific Lectin 3 or Laminin-Binding Protein
or IgE-Binding Protein or Lectin L-29.
The constant increase in the number of papers published in the most recent years and concerning
the role of this protein in many clinical conditions and diseases testify the great clinical relevance of
Gal-3 in human pathophysiology.
Numerous previous studies have indicated that Gal-3 may be used as a diagnostic or prognostic
biomarker for many types of diseases and conditions. Recently, the potential clinical uses of Gal-3 as
a diagnostic biomarker and as a therapeutic target were described in a comprehensive review [64].
The current review represents an attempt to examine the many clinical implications of Gal-3
protein, based on a classification of clinical diseases, listed in alphabetical order (Figure 3).
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Figure 3. Conditions and diseases in which a role for Gal-3 has been postulated, listed in
alphabetical order.
3. A
3.1. Asthma
Asthma is a heterogeneous disease characterized by chronic airway inflammation, variable and
reversible airway obstruction and airway hyperresponsiveness (AHR) [65]. Since their recognition,
almost fifty years ago, the class of human antibody officially named IgE was unequivocally considered
as the factor capable of transferring sensitivity to allergens and plays a central player in the allergic
response [66]. It is now clear that IgE acts as part of a complex protein network. The interaction
of genes belonging to such network with environmental factors is able to determine the risk of
allergic sensitization [67]. In addition to the two major IgE receptors, namely the FcεRI (high affinity)
and the FcεRII/CD23 (low affinity), Gal-3 has received increasing interest as a major player in this
network and is generally thought to be potentially relevant in the pathogenesis of inflammation in
asthma and its phenotypes. In this regard it is relevant to note that Gal-3 was initially identified
as an IgE-binding protein [68]. Several experimental studies, using murine animal models, indicate
that Gal-3 has a role in the pathophysiological mechanisms in immune response and, in particular,
in asthma [69–75]. The specific role of Gal-3 in asthma is related to its function in the recruitment,
activation and removal of neutrophils [73]. Experimental data from Gal-3 null mice showed reduced
neutrophil recruitment during infection [74] and Gal-3 increases uptake of apoptotic neutrophils.
Therefore, any Gal-3 dysfunction may influence the ability to remove apoptotic neutrophils from
the site of inflammation [75]. This has several consequences: Reduction in the removal of apoptotic
cells can result in the release of damaging enzymes and oxidants, which can promote persistence
of inflammation. In humans, a significant reduced level of Gal-3 was detected in the sputum of
neutrophilic asthma compared to eosinophilic and paucigranulocytic asthma [76]. However, the most
interesting finding was the recent observation that Gal-3 may be considered as a new biomarker
predictive of long-term responsiveness of pulmonary function in patients with severe asthma treated
with the monoclonal antibody, anti-immunoglobulin E (IgE), named omalizumab [77]. According to
this study, the analysis of bronchial biopsy specimens, obtained from patients with severe asthma,
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may help in predicting response to treatment. In particular, patients that were classified as Gal-3
positive before treatment initiation were responsive to the treatment with omalizumab while Gal-3
negative patients were non-responders to the same treatment with omalizumab. This study needs to
be confirmed by others but it indicates that Gal-3 may be considered as new asthma-related biomarker,
useful for patient stratification for therapy, in addition to the other biomarkers already known, such
as the fractional exhaled nitric oxide (FeNO) levels, the blood/sputum eosinophil counts, the serum
periostin levels, the smooth muscle proteins and the keratins.
Inflammation driven by type-2 helper T lymphocytes (Th2) is relevant in asthma and
understanding the mechanisms that underline Th2 cytokine production is crucial for the establishment
of novel therapeutic options. At present, there are limited data on the role of Gal-3 in allergic
inflammation. As a multifunctional protein expressed by different types of inflammatory cells, Gal-3
has been considered as an IgE-binding protein and a regulator of infiltrating cell inflammation,
activation and clearance [78]. Gal-3 activity may be operative in no-eosinophilic asthma [78].
Moreover, low levels of Gal-3 were seen in neutrophilic asthma compared with eosinophilic
asthma [76]. Furthermore, galectins in relationship with their location (extracellular or intracellular,
endogenous or exogenously delivered) may differentially regulate eosinophil behavior exerting
a pro- or anti-inflammatory outcome. In severe asthma Gal-3 may be considered as a biomarker
of lung remodeling and its levels are related to response to omalizumab treatment and improve
lung function [77]. Moreover, Gal-3 deficient mice developed less airway hyperresponsiveness and
eosinophils infiltration, a reduction of Th2 cytokines in the airways, during acute allergen-challenge if
compared to WT mice [69–71], suggesting a role of Gal-3 in the chronic asthma. In Brown-Norway rats
the intra-tracheal deposition of a vector with the gene encoding for Gal-3 causes the impairment of
some Th2 effects, eosinophil influx and the down-regulation of IL-5 gene expression, IL5 that is one of
the main regulatory cytokines that modulate eosinophilic behavior [79].
3.2. Atherosclerosis
Atherosclerosis is considered an inflammatory-proliferative response of the intima to injury [80,81].
The participation of monocytes in atherogenesis is well known [82,83] and their presence in the artery
plaques and in the lipid core was recognized in 1993 [84]. More recently, macrophages were recognized
as the principal inflammatory cell mediator in the atheromatous plaque that may participate in intima
remodeling, immune response, and scavenger functions through the synthesis and secretion of a variety
of enzymes and factors [80,85]. The role of Gal-3 in atherosclerosis was analyzed in specimens obtained
from carotid endarterectomies, lower limb amputations, and thoracic aortas from autopsies of young
adult trauma victims [86]. According to this study, a positive staining for Gal-3 can be detected close
to a lipid core or near areas with fibrosis, neovascularization, calcification, hemorrhage, or thrombosis.
In the carotid and lower limb arteries, foam cells were the cell type that most frequently stained
positive for Gal-3. Mononuclear round cells and foam cells containing Gal-3 were also observed in
the sub-endothelium, sometimes at sites of thrombosis. Endothelial cells and cells lining neo-vessels
within plaques were not stained for Gal-3. Spindle cells from the tunica media of atherosclerotic
arteries were not stained for Gal-3, but isolated Gal-3-positive cells were seen outside the lamina
elastica externa. Gal-3 can be detected by immunoperoxidase staining in advanced atherosclerotic
lesions of carotid and lower limb arteries and in early aortic atherosclerotic changes. In atherosclerotic
lesions, Gal-3 is often localized in macrophages and foam cells and rarely in smooth muscle cells. Gal-3
is not detectable by immunohistochemistry in the tunica media of umbilical cord, carotid, limb, and
aorta arteries. Finally, Gal-3 mRNA can be detected in advanced atherosclerotic lesions from carotid
and lower limb arteries and a higher level of Gal-3 was demonstrated by Western blot analysis in these
arteries in comparison with umbilical cord arteries.
The presence and the role of Gal-3 in most foam cells into the atherosclerotic lesions needs to be
elucidated. It could be related to an association with lipid loading or alternatively the accumulation
of Gal-3 together with advanced glycation endproducts (AGEs), may suggest that Gal-3 could act as
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a receptor for modified lipoproteins, thus participating in the formation of foam cells. More studies are
needed to unravel any pathogenic or diagnostic role of Gal-3 in atherosclerosis.
3.3. Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin condition that involves an inherited
epidermal barrier defect, which may allow for greater penetration by allergens and irritants.
Atopic dermatitis, commonly called atopic eczema, usually arises in early childhood, often in
infancy. While it usually resolves by early teenage years, approximately 5–10% of patients have the
disease extend into adulthood. Classic symptoms are itching and burning of the skin, resulting in
thickening of the skin in response to the scratching. In some adults, it can be severe with debilitating
itching, inability to sleep, and social stigmatization due to skin damage and thickening, often on the
face. IgE-associated atopic eczema/dermatitis syndrome (AEDS) contains abnormal B-cells that are
surface IgE-positive (sIgE+) and produce IgE spontaneously in culture. Gal-3 is highly expressed in
epithelial cells including keratinocytes, hair follicles, sebaceous, and sweat glands [87]. It has been
reported that the IgE production was amplified by PMNs in patients AEDS, but not in healthy controls,
and this effect was mediated by Gal-3 release by PMNs. In this regard, it has been demonstrated that IgE
release was enhanced by the addition of Gal-3 to the cultures of AEDS B cells admixed with PMNs from
healthy controls. These results suggest that Gal-3 can enhance PMN-induced IgE synthesis by B cells
that are already committed to IgE production. These observations indicate that Gal-3 may be involved
in the hyperactive immune response in AEDS [88]. Although initial evidence, based on the results of
immunohistochemical analysis of skin biopsies from AD patients, argued against a critical role of Gal-3
in the binding of monoclonal or serum Ig-E [89], many experimental results obtained using mouse
models of AD suggest that Gal-3 plays a critical role in the development of the allergic inflammatory
response in AD [90]. The possible involvement of Gal-3 in the development of an allergic inflammatory
response was, in fact, analyzed in an experimental mouse model in which AD was induced by repeated
epicutaneous sensitization with ovalbumin (OVA) [90]. In this mouse model an upregulation of Gal-3
expression in the epidermis was observed after such sensitization. These results suggest that Gal-3 is
a pro-inflammatory mediator of skin inflammation in atopic skin disease and that is required for the
development of the Th2 inflammatory response to epicutaneously-introduced antigens through its
effects on both DCs and T cells [90]. Based on these experimental results a company named “Galectin
Therapeutics Inc.” (NASDAQ:GALT, Norcross, GA, USA) has developed a new Gal-3 inhibitor, capable
of binding to Gal-3 and disrupting its function. A small, open label, investigator-initiated protocol
was recently started and three adult patients with severe atopic dermatitis, classified as refractory,
meaning that they have not responded to medical treatment beyond topical steroids, were successfully
treated without any significant adverse reaction [91]. A phase 2 controlled trial, using various doses
and regimens to further explore the drug’s potential, is now under way.
4. B
Blood Test
Clinical parameters, such as advanced age, higher New York Heart Association (NYHA)
functional class, reduced left ventricular ejection fraction (LVEF), lower body mass index, renal
dysfunction, and anemia, have all been associated with poor outcomes in heart failure (HF), but are
not significant predictors of mortality. Many efforts have been made recently to find biomarkers that
might help in the risk stratification, and prognostication of acute and chronic heart failure beside
the well-established markers, such as the brain natriuretic peptide (BNP) and its N-terminal part
(NT-proBNP), the soluble suppression of tumorigenicity 2 (ST2), the growth differentiation factor-15,
and the highly sensitive troponins.
In a pivotal paper published in 2004 by Sharma and colleagues [92] Gal-3 was identified as the
most upregulated protein in an animal model of left ventricular hypertrophy (LVH) and HF suggesting
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that Gal-3 is a critical player in the pathogenesis and progression of HF. Since then an acceleration of
research was observed, especially in the field of cardiology with many studies published concerning
the role of Gal-3 in the evaluation and management of patients with heart failure. Gal-3 levels in
plasma were, in fact, found to be positively associated with known cardiovascular risk factors, as age,
sex, diabetes, hypertension, hypercholesterolemia, body mass index, renal function and smoking
and was proposed as an additional prognostic factors, useful to identify high-risk patients in whom
additional care management efforts and advanced therapies could be warranted.
Gal-3 was proposed in many studies as a new biomarker of heart fibrosis that could predict
outcome of heart failure (HF) [93] and, in particular, occurrence of mortality [94,95]. In several
cohorts of acute HF [96,97], as well as chronic HF [94], Gal-3 was shown to be a powerful predictor
of mortality. Clinical effectiveness and prognostic value of this test have been demonstrated in
several heart-failure trials, including the “Coordinating Study Evaluating Outcomes of Advising and
Counseling in Heart Failure (COACH)” [97], the “Pro-BNP Investigation of Dyspnea in the Emergency
Department (PRIDE)” [98], the University of Maryland Pro-BNP for Diagnosis and Prognosis in
Patients Presenting with Dyspnea (UMD)” [99] and the “Heart Failure: A Controlled Trial Investigating
Outcomes of Exercise Training (HF-ACTION)” [100]. Gal-3 was also associated with mortality when
evaluated in the general population, as reported in the “Prevention of Renal and Vascular End-Stage
Disease (PREVEND) study [101], in the “Framingham Offspring Study” [102] and in the “Rancho
Bernardo Study” [103].
Finally, Gal-3 was associated with increased risk of developing AF in the Framingham study,
but this association was not found to be significant after adjustment for traditional clinical AF risk
factors [104].
Gal-3 is currently used in clinical practice and it is measured using many different blood assays
by manual or automated assays. The enzyme linked immunosorbent assay manual assay (ELISA) is
the most frequently used method in the published studies. Recently, FDA has approved for market
new automated blood assays, with faster delivery of the results, the BGM Gal-3 assay, manufactured
by BG Medicine, Inc. (Waltham, MA, USA) and the ARCHITECT Gal-3 assay, by Abbott Diagnostics
(Abbott Park, IL, USA) and more are on their ways. According to this tests plasma levels lower than
17.8 ng/mL indicate low risk, levels greater than 17.8 ng/mL but lower than 25.9 ng/mL are indicative
of moderate risk and levels above 25.9 ng/mL are associated with high risk of adverse outcomes and
need more frequent follow-up and intensified as well as advanced strategies of cure. Plasma Gal-3
levels greater than 25.9 ng/mL, independent of symptoms, clinical findings, and other laboratory
measures, predict a patient who is likely to have rapid progression of heart failure, eventually resulting
in hospitalization and death [105].
5. C
5.1. Cancer
A large body of reported data about galectin expression in cancer is available in the literature
and the chapter on Gal-3 action on cancer development and progression represents one of the most
relevant ones. Gal-3 has been shown to influence many significant biological processes linked to
cancer development and progression, including cell adhesion, proliferation, differentiation, mRNA
splicing, cell-cycle progression, immune system evasion, inflammation, angiogenesis, apoptosis and
metastasis [25,38,106–110]. In addition, Gal-3 exerts a role as a pro-tumor factor by acting within
the tumor microenvironment, the so-called “tumor niche”, to suppress immune surveillance. Its
ability to promote tumor cell proliferation and survival of the cancer cell both directly and indirectly,
by acting on cell adhesion and cell contact with mesenchymal stromal cells, has lead to consider Gal-3
as a guardian of the tumor microenvironment [111].
Gal-3 influences oncogenesis, cancer progression and metastasis through a variety of pathways
both inside and outside the cell [112–118]. The studies on the role of Gal-3 in different types of cancers
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indicate that such effects may be specific for the different types of cancer. In fact, Gal-3 may have both
positive and negative effects on cancer cell survival depending of the type of tumor considered and its
subcellular localization likely influences the role of Gal-3 in different cells [24–26].
5.1.1. Gal-3 Subcellular Localization in Tumor Tissues
In tumor tissues Gal-3 can be detected in the nucleus [119,120], in the cytoplasm [121],
and eventually can be secreted into the extracellular spaces [4] or in the circulation [122].
The localization of Gal-3 is essential to its function. Gal-3’s function, in fact, will vary depending on
whether it is in the nucleus, cytoplasm, or extracellular spaces [123]. In addition, as observed for Gal-1,
the effects of Gal-3 seem to be cell type specific [24,119,124–126]. All these factors make extremely
difficult to simplify the role of Gal-3 in cancer and may explain the variable and sometimes opposite
effects reported in different cells and in different cellular compartments.
5.1.2. Gal-3 and Apoptosis in Tumor Tissues
The most intensively studied mechanism through which Gal-3 influence cancer cell is represented
by its anti-apoptotic function [24,61,110,127]. The elucidation of the mechanisms through which
Gal-3 exerts its effect on apoptosis has led to identify a new apoptotic pathway in which different
types of DNA damage triggers the HIPK2 activation and induces p53 mediated repression of Gal-3
expression [128]. Dysregulation of this pathway due to the occurrence of p53 mutations or due to
HIPK2 loss may alter such pathway thus leading to Gal-3 overexpression and [129]. Gal-3 influences
also many other signal transduction cascades and pro-survival processes that include major oncogenes
such as RAS, BCL2, and MYC [130–137].
The ability of Gal-3 to form lattices with glycoproteins and glycolipids has been implicated in
regulating cell adhesion, metastasis, endocytosis, and other biological processes [138–143]. Aberrant
glycosylation could influence transport and trafficking of many different proteins involved in cancer
development and progression [143]. Interaction of Gal-3 with glycosphingolipid (GSL) resulted in
invaginations in the membrane that occurred during the endocytotic process and has been referred to
as “membrane bending” [140–143]. “Membrane bending” requires both Gal-3 and GSL. As of now,
integrin β1 endocytosis is mediated by GSL and Gal-3 and it is likely that other glycoproteins will also
be transported by this mechanism [143].
5.1.3. Gal-3 Immune Surveillance and Angiogenesis in Tumor Tissues
Gal-3 is able to modulate a variety of immune cell processes by co-opting selected inhibitory
receptors, disrupting co-stimulatory pathways and/or controlling activation, differentiation,
and survival of immune cells. On the other hand, Gal-3 can regulate vascular signaling programs
through binding to integrin avb3 or by sustaining the pro-angiogenic capacity of tumor-associated
macrophages. Therefore, Gal-3 serves as a bifunctional messenger that has emerged as a novel
regulatory checkpoint able to couple immunosuppression and angiogenesis, two events that occur
simultaneously during tumor growth and are often mediated by the same cytokines and the same
cell types [144].
5.1.4. Gal-3 in Various Types of Human Cancers
The large body of studies, regarding the expression of Gal-3 in various types of cancers that have
been published in the literature were obtained using different types of cells/tissues as well as various
animal models [38,106,145]. The specific techniques used, the inclusion of appropriate controls and the
heterogeneity of the tissues examined may explain the discrepancies observed in the different studies.
It is relevant to note that the percentage of normal epithelial, stromal, vascular and inflammatory cells
may constitute a strong bias in the evaluation of the expression of Gal-3 in a given cancerous tissue
specimens. This is especially true for Gal-3, a protein that is highly expressed in inflammatory cells.
In general, histological techniques such as immunohistochemistry or in situ hybridization that allow
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a cell type-specific analysis of Gal-3 expression are most reliable, compared to Western blot and RT-PCR
techniques that may be give results that are potentially contaminated or diluted by the presence of
noncancerous cells. Gal-3 was analyzed as oncologic marker both by immunohistochemistry and by
measuring its blood levels.
An increased expression of Gal-3 was observed at immunohistochemistry or at RT-PCR, in
many different types of cancers [25,146,147] and most of the authors agree that detection of Gal-3
could help to better define diagnosis and/or prognosis of cancer. Increased expression of Gal-3 was
reported breast carcinoma, in colon carcinomas, in gastric cancers, in hepatocellular carcinoma, in well
differentiated thyroid carcinomas in anaplastic large-cell lymphoma, in head and neck squamous cell
carcinomas, in tongue carcinomas and in non-small cell lung cancer. Other studies demonstrated an
opposite picture, with decreased Gal-3 expression in breast, ovarian cancer prostate tumors, advanced
uterine adenocarcinoma, basal cell carcinoma of the skin, epithelial skin cancer and malignant
salivary gland neoplasms, compared to the corresponding normal tissue. Several studies have
investigated the expression of Gal-3 in in human colon carcinomas, but conflicting results have
been reported [148–151]. It seems that Gal-3 expression is down-regulated in the initial stages of
colon neoplastic progression [152,153], whereas a dissociated cytoplasmic expression increases in later
phases of tumor progression [154].
Among the cancers that express high level of Gal-3 there are those affecting the thyroid
gland [155–161], the central nervous system in adults [162] and in children [163,164], the head and
neck squamous cell [165], the pancreas [166], the stomach [112], the bladder [167], the kidney [168,169],
the liver [170], in the parathyroid [171,172] and in the salivary glands [173]. In addition, elevated Gal-3
expression levels were also observed in lymphoma [174] and in melanoma [175]. Finally, Gal-3 was
found to play a relevant prognostic role in neuroblastoma [164].
The analysis of the expression levels of Gal-3 was extensively studied in the thyroid tissue.
In this tissue, Gal-3 expression analysis was suggested as a presurgical marker of cancer [156] and
the detection of Gal-3 expression, specifically located in the cytoplasm of the thyroid cells was used
a diagnostic hallmark of thyroid malignancy. On such basis a ThyroTests was setup [176–178], clinically
validated [160,179] and used in many countries [180]. Its good accuracy and its low cost has led to
propose its inclusion in the diagnostic algorithm of thyroid cancer as a screening test especially useful
for suspicious thyroid nodules with a cytologically indeterminate pattern [181,182].
In addition to the analysis of the expression levels in neoplastic tissues, Gal-3 was also investigated
as a potential new oncologic scintigraphic as well as blood marker in many different types of tumors,
including the thyroid [183–185], the prostate [186] and the ovarian cancer [187].
5.2. Cerebral Infarction
It is often difficult to determine the prognosis and clarify the pathophysiology of patients referred
to emergency department for suspected ischemic stroke. Computerized cranial tomography (CCT)
and diffusion-weighted magnetic resonance imaging (MRI) are crucial in the diagnosis of cerebral
infarction. However, a lot of efforts have been made to search for new biomarkers and, in particular,
for serum markers specifically associated with brain damage, that may allow discrimination of
ischemic stroke and intracerebral hemorrhage. The levels of Gal-3 have been reported to increase in
ischemic brain damage [188,189]. In a recent study, Gal-3 serum levels were found to be increased in
clinically-suspected ischemic stroke patients with normal CCT, seen in the emergency department.
On such basis, it has been suggested that its measurement may contribute to the diagnosis of cerebral
infarction [190]. Such promising studies need to be confirmed in large numbers of patients.
5.3. Chronic Obstructive Pulmonary Disease
At present there are limited data available on the possible role of Gal-3 in chronic obstructive
pulmonary disease (COPD). COPD is a chronic, progressive, irreversible disease associated with
high morbidity and mortality. It is characterized by bronchial epithelial changes and neutrophil
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infiltration. Gal-3 has been demonstrated to be higher in patients with COPD with elevated systolic
pulmonary artery pressure compared to healthy controls [191]. In this subset of patients, Gal-3
levels seem to be a predictive marker of right ventricular dysfunction [191]. In small airways of
severe COPD patients, epithelial Gal-3 immunostaining was increased when compared with healthy
nonsmokers or smokers [192]. In addition, in patients with severe COPD, Gal-3 expression and
neutrophil accumulation in the small airway epithelium correlate with epithelial proliferation and
airway obstruction [192]. Finally, in the airway of current or ex-smoker COPD patients, Gal-3 and its
receptor CD98 were decreased. Furthermore, Gal-3 levels measured in broncho alveolar lavage (BAL)
were reduced in healthy smokers suggesting a potential role of smoke in regulating Gal-3 expression
although in COPD ex-smokers the defect in Gal-3 expression persists despite cessation of smoking [193].
Administration of exogenous Gal-3 to alveolar macrophages from BAL, cultivated in vitro and obtained
from patients affected by COPD, caused an increase in efferocytosis, the process by which dying/dead
cells (e.g., apoptotic or necrotic) are removed by phagocytic cells, thus indicating a possible role of
Gal-3 as a novel macrophage-targeted therapies for COPD/Emphysema [194]. Very recently, the level
of serum Gal-3 was significantly increased in acute exacerbation of COPD compared with the level
in COPD convalescence phase, suggesting that Gal-3 might be a valuable diagnostic biomarker for
this condition [195]. In such patients, the serum levels of Gal-3 positively correlated with systemic
inflammation and smoking [195].
6. D
6.1. Degenerative Aortic Stenosis
The first clinical report concerning the relationship between myocardial Gal-3 expression
and severe aortic stenosis (AS) was published in 2004 [92]. In this study, Gal-3 expression was
analyzed in cardiac biopsies from patients undergoing aortic valve replacement for aortic stenosis.
Gal-3 myocardial expression was increased in aortic stenosis patients with cardiac hypertrophy and
relatively depressed ejection fraction compared to aortic stenosis subjects with LV hypertrophy and
normal or elevated ejection fraction.
Recently, another study was conducted to test the potential prognostic value of Gal-3 in patients
with degenerative AS [196]. In patients treated with balloon aortic valvuloplasty (BAV) Gal-3 was
associated with worse survival and this was unrelated to estimated glomerular filtration rate (eGFR).
Measurement of circulating levels of Gal-3 may therefore be useful in risk stratification in elderly
patients affected by degenerative AS with coexistent diseases to choose the optimal therapy.
6.2. Diabetes Mellitus
Whereas most of the experiments revealed a protective role of Gal-3 in acute inflammation,
its function in chronic inflammatory diseases, like diabetes mellitus (DM) and in particular in type 2
diabetes mellitus (T2DM) is less clear [197,198]. The role of Gal-3 in the development of Diabetes of its
complication is still an area of debate. Several studies indicate that Gal-3 is involved in the regulation
of glucose homeostasis by acting at the level of adipose tissue and pancreatic islets, thus participating
in the pathogenesis of obesity and T2DM, but its effects may be influenced by differences in genetic
background, diet, age, sex, as well as experimental end points. In fact, in the literature controversial
results have been reported regarding to the roles of Gal-3 in the pathogenesis of T2DM. In some
studies Gal-3 was considered as a protective factor, while in others it was found to be associated with
an increase in the severity of T2DM.
6.2.1. Gal-3 Increases Severity of DM
In humans, systemic Gal-3 is elevated in obesity and negatively correlates with glycated
hemoglobin in T2DM patients [199]. In a population-based cross-sectional survey in Zhejiang, China
involving large number of patients, high Gal-3 serum levels were associated with increased odds of
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developing heart failure, nephropathy, and peripheral arterial disease in patients with T2DM [200].
In other clinical studies, circulating Gal-3 was higher in T2DM patients [201–203] and thought to
be a risk factor for vascular complications, such as heart failure, nephropathy, peripheral artery
disease, and other vascular complications. Patients with Gal-3 level > 25 ng/mL exhibited a 11.4-fold
higher risk of microvascular complications (retinopathy and/or nephropathy) and a 8.5-fold increased
risk of macrovascular complications (myocardial infraction, angina pectoris, cerebrovascular event,
and peripheral artery disease) compared to patients with Gal-3 level < 10 ng/mL [200]. The order of
circulating level of glectin-3 was as follows: Diabetes > prediabetes > normal control. Therefore, it has
since been considered as a marker for prediabetes [201]. In diabetic patients, Gal-3 concentrations
were significantly elevated in subjects with coronary artery disease and associated with the formation
of diseased vessels and plaques [203]. In agreement with human studies, also in mice models in
which hyperglycemia was induced after high-fat diet feeding with a corresponding threefold increase
in homeostasis model assessment for insulin resistance (HOMA-IR) index and a 1.5-fold decrease
in Akt activation, indicate that Gal-3 expression was increased in endothelial cells as well as in
blood, suggesting that Gal-3 plays a role in the vascular response in DM [204]. Another report found
increased Gal-3 expression in mice fed with a high-fat diet and recombinant human Gal-3 promoted
preadipocyte proliferation [205]. Moreover, galecitin-3 knockout mice exhibited less weight gain
when fed with a high-fat diet. The expression levels of PPAR-γ, CCAAT-enhancer-binding protein
alpha (C/EBPα), CCAAT-enhancer-binding protein beta (C/EBPβ), and fatty acid binding protein 4
(Fabp4) were also reduced in the adipose tissue of Gal-3 knockout mice fed with a high-fat diet [206].
Gal-3 upregulation was also found in hepatocytes treated with 100 mM d-glucose and in the sera
of patients with T2DM [207]. Consistently, Gal-3 ablation protected mice from the development of
streptozotocin-induced type 1 DM (T1DM) [208].
6.2.2. Gal-3 Decreases Severity of DM
Although most of the studies agree in considering Gal-3 as a marker of inflammation and fibrosis,
many studies suggest that the increased expression of Gal-3 may be part of an adaptive response to
tissue injury, favoring resolution of inflammation and opposing to chronification of the inflammatory
process [209]. Both clinical studies in humans and experimental studies in mice, indicate that Gal-3
may indeed play a protective role in some metabolic diseases, such as T2DM. In a study of 20 patients,
Ohkura et al. measured the glucose disposal rate, fasting insulin, HOMA-IR, insulin sensitivity index,
Gal-3, and adiponectin. Notably, Gal-3 levels negatively correlated with fasting insulin and HOMA-IR,
but positively correlated with glucose disposal rate, insulin sensitivity index, and serum adiponectin
level [210]. Moreover, body weight, amount of total visceral adipose tissue, fasting blood glucose,
and insulin levels increased in high-fat diet-fed Gal-3 knockout mice. These mice also displayed
enhanced Th1 T-cells and natural killer T (NKT) cells, as well as pro-inflammatory CD11c+CD11b+
macrophages, whereas the number of anti- inflammatory CD4+CD25+FoxP3+ regulatory T-cells and
M2 macrophages were reduced. Infiltrating pancreatic and peritoneal macrophages also exhibited
significant increases in NLR family, pyrin domain containing 3 (NLRP3) inflammasome, nuclear
factor-κB activity, and IL-1β production [211]. Gal-3 deficiency in mice led to the accumulation of fat
as well as increased inflammation in adipose tissue, which is important in promoting insulin resistance.
There were higher numbers of infiltrated macrophages and inflammatory cytokines, IL-6 and TNF-α,
in the adipose tissue. High-fat diet also attenuated the expression of adiponectin and PPAR-γ in
the adipose tissue [212]. Furthermore, galecitin-3 deficiency was also found to suppress endothelial
glucose transporter, type 4 (GLUT4) expression and promote insulin resistance in high-fat diet-fed
mice, as suggested by comparing Gal-3 knockout mice to wild-type controls [213]. Experimental
studies, performed in mice, demonstrated a protective role of Gal-3 toward obesity and T2DM,
via the modulation of the responsiveness of innate and adaptive immunity to overnutrition [212,214].
In accordance with such hypothesis, Gal-3 KO in mice induces a pro-inflammatory phenotype
characterized by an increased systemic, pancreatic and VAT inflammatory response to metabolic
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stimuli and an exacerbated vascular and renal tissue damage induced by diabetes and related
disorders [215,216]. Moreover, Gal-3 deficient mice exhibit greater hyperglycemia and impaired
glucose tolerance compared to control wild type mice, indicating that Gal-3 deficiency contributes to
the pathogenesis of diabetes [213].
The conflicting data reported so far regarding the role Gal-3 in obesity and T2DM suggest that we
need of further attention and more clinical studies in order to clarify its role as a potential player and
therapeutic target in these conditions.
7. E
7.1. Endometriosis
Endometriosis is an inflammatory disease of reproductive-aged women, and it is strongly related
to consequent infertility [217]. Endometriosis is caused by a dysregulation of inflammatory and
vascular signaling [218]. Gal-3 plays a relevant role in both these processes and it is overexpressed
in endometriotic tissue [219]. In addition, higher levels of Gal-3 can be detected in the peritoneal
fluids from women with endometriosis [220]. Another aspect in which Gal-3 may be involved in
the pathogenesis of endometriosis and its complication in the development of pain associated with
inflammation. Gal-3 was found to be involved in myelin phagocytosis, in Wallerian degeneration of
neurons, and is able to trigger neuronal apoptosis after nerve injury [221]. It has been hypothesized that
Gal-3, overexpressed in endometriotic foci, could be responsible for the induction of nerve degeneration
and pain [222]. In this regard it is interesting to note that neurotrophin, a nerve growth factor strongly
expressed in endometriosis, upregulates galcetin-3 expression [219]. All of these studies suggest that
Gal-3, and other Galectins as well, play important roles in immune responses in inflammatory disease
and in the pathogenesis of endometriosis, but there is still need of high-quality clinical studies to
confirm these observations.
7.2. Enteric Nervous System
The enteric nervous system (ENS) governs the function of the gastrointestinal (GI) tract. It is
embedded in the lining of the gastrointestinal system, beginning in the esophagus and extending
down to the anus [223]. It is derived from neural crest cells and is often named as the second
brain [224,225]. Dysfunction of ENS, due to ischemic cerebral stroke, may be responsible for the
occurrence of neurological manifestation that complicate stroke, including dysphagia, dysmotility and
colorectal dysfunction.
It is well known that Gal-3 in the GI tract stabilizes cell-cell junctions and enables polarization of
intestinal epithelial cells [226,227]. Furthermore, it has been associated with GI cancers [228], as well
as with Crohn’s disease and ulcerative colitis [229].
Induction of stroke in experimental murine models by permanent middle cerebral artery occlusion
(pMCAO) triggers central and peripheral Gal-3 release by microglia. Increased levels of Gal-3 are,
in turn, responsible for enteric neuronal loss [230]. Gal-3, therefore, appears to be a crucial mediator of
the GI damage observed after brain injuries, directly at the level of enteric neuronal cells and it may
represent a potential new target for the treatment of post-stroke gastrointestinal complications. In this
regard, it has been recently reported that elevated serum levels of Gal-3 correlates with poor outcome
after acute heart failure and high Gal-3 values are observed in heart failure patients with a history
of stroke [231].
7.3. Encephalitis
Gal-3 is expressed in a variety of glial cells of the central nervous system (CNS) tissues [232] and
contributes to the migration of neuroblasts during brain development [233] and to the differentiation
of oligodendrocytes [232]. Since Gal-3 is involved in inflammatory response and in the interaction
with extracellular matrix, a potential role has been postulated in various types of CNS inflammation
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and in particular in viral encephalitis. Its expression was analyzed in some neuroinflammation
animal models. It has been reported that Gal-3 is upregulated after long-term virus inoculation in
a Junin virus-induced encephalitis model using newborn mice [234]. Gal-3 is rapidly upregulated in
activated microglia, in the encephalomyocarditis virus-induced adult mouse encephalitis model of viral
infection [235]. Gal-3 was found to be expressed in macrophages in remote spinal cord dorsal horn
lesions caused by peripheral inoculation of herpes virus [236].
8. F
Fibrosis
Tissue fibrosis is characterized by the occurrence of tissue overgrowth, hardening, and/or
scarring [237]. Tissue fibrosis may progressively evolve toward a severely debilitating disease,
characterized by superabundant accumulation of extracellular matrix (ECM) including collagen. Tissue
fibrosis represents the end result of chronic inflammatory reactions induced by a variety of stimuli
including persistent infections, autoimmune reactions, allergic responses, chemical insults, radiation,
and tissue injury and ultimately may lead to excessive tissue scarring, organ injury, function decline,
and even failure [238–240]. Fibrosis is generally considered a major cause of morbidity and mortality
worldwide because therapeutic options for the treatment of tissue fibrosis are rather limited. The only
effective treatment in end-stage fibrotic disease is often represented by the organ transplantation.
It is well-known that the mechanisms driving fibrogenesis are distinct from those regulating acute
inflammatory reactions but few clear pathogenic and therapeutic targets have been identified so far.
Recently, Gal-3 has emerged as a key regulator of chronic inflammation and tissue fibrogenesis and as
an attractive new therapeutic target in the search for effective anti-fibrotic therapies [241].
Many studies indicate that Gal-3 is increased in patients with fibrosis affecting different tissues.
In particular, Gal-3 is associated with fibrosis affecting the liver [170,242], the kidney [243,244],
the lung [245,246], the heart [247,248] as well as the nervous system [249]. In addition, Gal-3 was found
to be associated with systemic sclerosis (SSc), and in particular with skin fibrosis and proliferative
vasculopathy observed in such condition [250]. Recently, another study indicated that the serum
Gal-3 levels were higher in the SSc patients group compared with the controls group and they were
higher in the active SSc group than in the inactive SSc group [251]. These data suggest that Gal-3 may
be considered as a prominent biomarker of disease activity in SSc. In these studies examining the
pathogenic role of Gal-3 in fibrosis, Gal-3 is identified as the link between macrophages, fibroblasts
and the pro-fibrotic phenotype. It is known, in fact, that Gal-3 mediates IL-4 induced alternative
macrophage activation and that IL-4/IL-13 activated macrophages upregulate profibrotic genes,
stimulating matrix production and enhancing fibrosis [252–254]. These observations have led to the
concept of a Gal-3/macrophage/fibroblast “axis”.
On the basis of such observations regarding the profibrotic role of Gal-3, the measurement of
its serum levels was proposed as a new prognostic factor [101]. In the Prevention of REnal and
Vascular ENd-stage Disease (PREVEND), serum Gal-3 levels were measured in 7968 subjects that were
followed-up for of approximately 10 years. Gal-3 serum levels were correlated with established risk
factors for CV disease and mortality in subjects from the general population and gradually increased
with age. After correction for such classical CV risk factors (smoking, blood pressure, cholesterol and
diabetes) the fibrosis marker Gal-3 independently predicted all-cause mortality. The same observation
was recently reported for patients with systemic sclerosis where Gal-3 was found to be the best predictor
of the all-cause mortality in a group of 152 patients with systemic sclerosis that were followed-up
for up to 10 years [255]. All these results indicate that Gal-3 may be considered as a useful new
simple biomarker in the prediction of future CV events and mortality and its inhibition may represent
a promising therapeutic strategy against tissue fibrosis.
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9. G
Gastritis
Numerous infectious agents, such as Trypanosma cruzi [256], human immunodeficiency virus-1 [257]
and the human T-lymphotropic virus-1 [258], have been reported to be able to induce Gal-3 upregulation.
The first report regarding the association between Gal-3 and gastritis due to Helicobacter pylori infection
was published in 2006 [259]. This study demonstrated that the expression of Gal-3 was upregulated
by gastric epithelial cells following adhesion of Helicobacter pylori, suggesting that in addition to
colonization this protein also plays a role in the host response to infection. Murine experimental
models have recently confirmed the key role played by Gal-3 in the innate immunity against infection
and in the colonization of gastric mucosa by Helicobacter pylori [260]. Administration of extracellular
recombinant Gal-3 (rGal-3) was shown to inhibit the adhesion of H. pylori to the gastric epithelial
cells resulting in a decrease in apoptosis. Gal-3 acts as a chemoattractant in the recruitment of
THP-1 monocytes, working as a negative regulator of Helicobacter pylori infection and its effects on
gastric mucosa [261]. Since there is a strong association between Helicobacter pylori infection and the
development of gastric adenocarcinoma and mucosa-associated gastric lymphoma [262,263], it has
been suggested that the expression and upregulation of Gal-3 may act a critical endogenous event in
Helicobacter pylori infection that interferes with various intracellular events, causing prolonged cell
survival, which is characteristic in carcinogenesis [264].
10. H
10.1. Heart
Although Gal-3 is expressed at a low constitutive expression level in the heart, under
pathophysiologic conditions, the level of expression of Gal-3 may change substantially and, therefore,
may play a prominent function.
The first observation regarding the role of Gal-3 in heart failure was published in 2004 [92].
In this study, performed on a rat model of severe hypertension and overt heart failure, the Gal-3 was
the strongest regulated gene, being overexpressed in decompensated hearts. A more than five-fold
upregulation was observed in rat with decompensated hearts compared to those with compensated
hearts. These results were confirmed in human heart tissues, in the same study. Gal-3 expression
analysis, performed in ventricular biopsies from patients with aortic stenosis with preserved versus
depressed ejection fraction demonstrated an upregulation in the myocardial biopsies from patients
with depressed ejection fraction.
The demonstration that Gal-3 is responsible for the induction of left ventricular remodeling
and development of heart failure came from experimental studies, using rats in which Gal-3 was
infused in the pericardial sac [265]. The structural and functional modifications of the rat myocardial
tissues were prevented by the co-administration of N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP),
a naturally occurring tetrapeptide, acting as a Gal-3 inhibitor. The mechanism of action of Gal-3 at
the myocardium level is not entirely clarified yet and it may be a general event in left ventricular
dysfunction caused by different etiologies. Once Gal-3 is overexpressed it is responsible for activation
of fibroblasts and macrophages and consequent induction of fibrosis, scar production and, ultimately,
of cardiac remodeling. Gal-3 appears to be involved in the control of interstitial fibrosis, especially in
the overloaded hearts [266]. The demonstration of the role of myocardial Gal-3 expression in heart
failure has prompted some authors to evaluate the possibility that Gal-3 serum levels may be useful
in the diagnosis of acute heart failure in patients presenting with dyspnea [96]. According to what
suggested by Kramer [267], all the clinical trials evaluating Gal-3 in cardiovascular disease patients
can be categorized into four groups of studies, according to their aim:
• assessing the utility of the serum/plasma concentration of the lectin for diagnosis,
• helping in stratifying patients for therapy,
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• monitoring therapy response, and
• predicting short- and long-term morbidity and mortality.
The clinical utility of Gal-3 in the diagnosis of heart failure was not clearly demonstrated and,
in particular, Gal-3 did not show correlation with the NYHA functional classification of patients and,
in addition, it showed lower specificity and sensitivity in identifying heart failure, as compare to
the NT-proBNP [96,268]. Gal-3 proved to be more useful in as a marker for patient stratification
for therapy. Low levels of serum Gal-3 (<19 ng/mL) were associated with better survival rates and
lower cardiovascular event rates in patients treated with rosuvastatin therapy [269]. Other evidence
regarding the clinical utility of Gal-3 in stratification for therapy came from the Multicenter Automatic
Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) study [270].
In this study, patients with high baseline Gal-3 levels (in the top quartile of the distribution) benefited
more (65% reduction in risk of the primary end point) from cardiac resynchronization therapy
compared to those with lower baseline Gal-3 values (25% decrease in risk). The clinical utility of
Gal-3 measurement in the serum as a marker for monitoring therapy was evaluated in patients that
underwent to left-ventricular assist device (LVAD) implantation [271,272]. In such patients, however,
unloading of the heart did not influence plasma Gal-3 levels within the first 30 days after device
implantation. Gal-3, therefore, did not provide sufficient discrimination for prediction of outcome.
Much more promising are the studies regarding the clinical utility of Gal-3 measurement in the
serum in predicting short- and long-term morbidity and mortality [94,101,105,273,274]. Many different
clinical trials have been conducted so far to test the prognostic value of Gal-3 in patients with heart
failure as well as in the general population. Gal-3 proved to be associated with mortality in 232 patients
with chronic heart failure, followed for 6.5 years. Gal-3, therefore, represents a significant predictor of
mortality risk in patients with heart failure, after adjustment for age and sex, and severity of HF and
renal dysfunction, as assessed by NT-proBNP and estimated glomerular filtration rate, respectively [94].
On the basis of such evidence the Gal-3 blood test was proposed in the evaluation of patients with
heart failure [105] and in the management of acute heart failure patients presenting to the emergency
department [275]. Much interest came form the Prevention of REnal and Vascular END stage disease
(PREVEND) clinical trial, the largest study with the longest observation period, aimed to investigate
Gal-3 levels to date [101]. In such study a total of 7968 Caucasian individuals from the general
population were examined and followed up for 10 years. It is interesting to note that Gal-3 serum
levels increase with age and that females showed higher values than males. This study demonstrated
that there is a clear association of Gal-3 serum levels and increased all-cause mortality, suggesting that
measurement of Gal-3 in the serum may be useful not only to predict outcome in patients with heart
failure but also in the general population.
At the present time, current guidelines indicate that the measurement of biomarkers of
fibrosis, such as soluble ST2 and Gal-3, may be considered for additive risk stratification (class of
recommendation IIa, level of evidence A) [276–278].
10.2. HIV
Human immunodeficiency virus (HIV) triggers decreases in both the number and function of CD4+
T lymphocytes. Its replication cycle consists of three stages: Attachment and entry, gene and protein
expression and assembly and budding. Gal-3 was found to play a role in HIV-1 viral budding [279].
After infection HIV-1 can survive for a long period without gene expression in host cells or can cause
continuous viral expression without cytopathic effects on the cells. HIV-1 principally targets CD4+ T
cells and cells of the monocyte/macrophage lineage [280].
A specific role of Gal-3 expression in HIV infection was hypothesized many years ago. Gal-3 was
found to be associated with early stages of HIV infection, in particular during transport and/or splicing
of HIV mRNA. Gal-3 expression greatly increases after infection of Molt-3 cells with HIV type 1,
concomitantly with the onset of expression of Tat protein [281]. The increase in Gal-3 expression
was mediated at the transcriptional level. Gal-3 promoter, in fact, was significantly upregulated
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by expression vectors encoding the 40-kDa Tax protein, a potent transactivator in HTLV-1 [258].
Subsequent studies demonstrated that Tat protein expression is able to induce an upregulation of
Gal-3 in several human cell lines, by means of Tat transactivation of Sp-1-rich regulatory sequences
upstream of the Gal-3 gene [257]. The role of Gal-3 in HIV infection however, is not entirely elucidated
yet. The effect on HIV infection, however, seems to be different, and perhaps opposite, from those
exerted by Gal-1 [282]. Recently, it has been suggested that Gal-3 may be involved in the host response
to HIV infection. According to this study, Gal-3 is induced in HIV-1-infected macrophages and may
promote death of HIV-1/SIV-infected macrophages, thus contributing to eradicate HIV infection [283].
11. I
11.1. Inflammation
Besides its known expression in epithelial and endothelial cells, Gal-3 is also expressed in
many different cells involved in mediating inflammatory response, such as macrophages [284],
monocytes [285], dendritic cells [286], eosinophils [287], mast cells [288], natural killer cells [289], as well
as T lymphocytes [290] and activated B lymphocytic cells [291]. In addition, Gal-3 is overexpressed in
phagocytic macrophages and is, therefore, considered as a macrophage activation marker [292]. The role
of Gal-3 in inflammation has been extensively reviewed in many studies [197,291,293–295].
Gal-3 is involved in many processes during the acute inflammatory response including neutrophil
activation and adhesion [296], chemoattraction of monocytes⁄macrophages [285], opsonization of
apoptotic neutrophils [75], and activation of mast cells [297]. Gal-3 is abundantly expressed and
secreted by macrophages [298]. Furthermore, expression of Gal-3 is increased when monocytes
differentiate into macrophages [298] and decreased when immature dendritic cells differentiate into
mature dendritic cells [299]. Gal-3 also augments monocyte–monocyte interactions that lead to
polykaryon (multinucleated giant cell) formation, a phenotype associated with alternative macrophage
activation [300].
Since the role of neutrophils is considered crucial with respect to the immune response to microbial
agents, several studies have investigated also the relationship between Gal-3 and neutrophils activation
and migration. By using a murine pneumonia model system, Gal-3 was found to be accumulated into
the alveolar space, following induction of pneumonia with Streptococcus pneumoniae and that this event
correlated with the onset of neutrophil extravasation [301]. Interestingly, the accumulation of Gal-3 in
lung was not observed during neutrophil emigration into alveoli induced by Escherichia coli infection.
Thus, this effect appears to be specific for the alveolar infection caused by Streptococcus pneumoniae.
In addition, Gal-3 was found to display antimicrobial activity against the fungus
Candida albicans [302].
Gal-3 effects on monocyte–monocyte interactions are also involved in chronic inflammatory and
fibrotic diseases [303]. However, its role is complex and both pro-fibrotic and protective roles for Gal-3
have been reported in models of chronic inflammation and fibrogenesis. To further complicate the
story, the effects of Gal-3 appear to be dependent on both the organ and type of injury model analyzed.
Chronic inflammation with resultant fibrosis, loss of tissue architecture, scarring and subsequent
organ failure characterizes the pathogenesis of many chronic human diseases and is a major cause
of morbidity and mortality. Tissue fibrosis is mediated by the fibroblasts and myofibroblasts, which
represent key cells in the initiation and perpetuation of tissue fibrogenesis [304] and by the macrophages
themselves, which are involved, in the same time, in both the evolution and resolution of tissue
fibrosis [305]. Gal-3 and Gal-1 are potent mitogens for fibroblasts in vitro. Gal-3 is able to stimulate
DNA synthesis and cell proliferation in quiescent cultures of normal human lung fibroblast [306] as
well as in fibroblast from different tissues [307].
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11.2. Interstitial Lung Disease
Interstitial lung diseases are a wide group of lung diseases in which the pathologic process
involves the interstitium. Among these diseases, idiopathic pulmonary fibrosis (IPF) represents
a separate nosographic entity, characterized by rapid progression toward lung failure and dead. IPF is
characterized by restriction in lung capacity, due to scarring of lung tissue. IPF is an orphan condition
that affects between 200,000 and 300,000 subjects in the Western world. Current therapies have little
effect on the natural course of the disease and only partial treatment options are available. There are
few studies in experimental mouse models and in humans on the role of Gal-3 addressing this issue.
Gal-3 was increased in a mouse model of bleomycin induced lung fibrosis [308]. In humans, Gal-3 was
increased in the serum of patients affected by IPF, and higher Gal-3 concentrations were associated
with decreased lung volumes and altered gas exchange [309]. Furthermore, the increase of Gal-3
has been documented in the broncho-alveolar lavage fluid (BALF) from patients affected with IPF
and this increase appear to be specific for IPF and interstitial pneumonia associated with collagen
vascular disease (CVD-IP) because patients with other interstitial lung disease such as the cryptogenic
organizing pneumonia/bronchiolitis obliterance organizing pneumonia (COP/BOOP), the acute
hypersensitive pneumonia and the Pneumocystis jiroveci infection did not show any significant increase
of Gal-3 in the BAL fluid [246]. The increase in Gal-3, measured in the BAL fluid was associated with an
increase of Gal-3 protein expression inside the alveolar macrophages, detected by immunofluorescence.
Gal-3 is produced and secreted by alveolar macrophages and its induction may be determined by
pro-inflammatory cytokines. It is well known that TNF alpha, a pro-fibrogenetic cytokine, is able
to induce in vitro Gal-3 production by macrophage/monocyte cell line model [310,311]. A positive
feedback between TNF alpha and Gal-3 was hypothesized based on the ability of Gal-3 to induce TNF
alpha production sustaining inflammation [246]. It was also reported that Gal-3 might participate in
vascular remodeling, known to be present in fibrotic lung [312]. In this regard, Gal-3 was able to induce
capillary tube formation of endothelial cells in vitro and to stimulate angiogenesis in vivo [313]. Gal-3
action on neovascularization observed in IPF may be due to both a direct effect on endothelial cells and
an indirect effect through IL 8 production [246]. Based on the assumption that Gal-3 is responsible for
a promoting effect on IPF and considering the lack of effective treatment for this pulmonary condition,
it has been postulated that Gal-3 may represent a possible new target for treatment. According to
this hypothesis, the inhibition of Gal-3 expression and activity would result in an amelioration of
the clinical conditions of patients affected. Taking advantage of a new compound named TD139,
a highly potent, specific inhibitor of the galactoside binding pocket of Gal-3 a novel target therapy
for IPF was proposed and a clinical trial process was started in 2014. TD139 was formulated for
inhalation, which enables direct targeting the fibrotic tissue in the lungs, while minimizing systemic
exposure. A randomized, double-blind, multi-centre, placebo-controlled, multiple dose expansion
cohort study, was designed to assess the safety, tolerability, PK and PD of TD139 (ClinicalTrials.gov
Identifier: NCT02257177). Galecto Biotech Company recently announced the successful completion
of phase Ib/IIa clinical trial of inhaled TD139, administered to human volunteers and IPF patients.
The possibility to treat IPF by targeting Gal-3 molecule offer the chance to better treatment of such
devastating disease and open a new era on the clinical use of Gal-3 antagonists.
12. J
Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is characterized by hyperplasia of synovial cells and
accumulation of mononuclear inflammatory infiltrates. Such accumulation is generally thought
to be due to the alteration of the local balance between cell proliferation and apoptosis. In agreement
with this hypothesis, patients with polyarticular juvenile arthritis showed low apoptotic indexes,
accompanied by low Bcl-2 expression, low proliferation rates and upregulation of Gal-3 expression
in their synovial tissue [314]. Gal-3 upregulation in the synovial tissues was suggested to be the
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cause of the defective mononuclear apoptosis observed in synovial inflammatory infiltrates from these
patients. Other evidence derives from the studies that have measured the serum levels in patients
affected by JIA. Gal-3 serum levels were increased in a group of 50 active JIA children, compared
to control subjects [315]. In addition, a positive correlation was demonstrated between serum Gal-3
levels and disease activity, i.e., the higher the level during exacerbations the higher it remained
after remission. Finally, in such juvenile patients, the synovial fluid Gal-3 levels were found to be
increased (approximately three times higher) compared to the serum level in paired samples. All these
observations indicate that Gal-3 plays a crucial role in the pathophysiology of Juvenile idiopathic
arthritis. Further studies including larger number of patients are needed, but it can be postulated that
Gal-3 would be used in the future as a new biomarker for JIA disease, indicating activity, severity and
progression of disease.
13. K
Kidney
Gal-3 is expressed during embryogenesis and regulates branching morphogenesis and
metanephrogenesis [316]. Gal-3 plays a role also in the adult human kidney [317,318]. In normal
adult kidneys, its expression is restricted to the collecting tubules and primary cilium. However,
it has been reported in rats that its expression can be temporarily re-induced during regeneration
after tissue injury [319]. Experimental studies, performed in mice and rats, demonstrated that Gal-3
is markedly upregulated in acute tubular injury and the subsequent regeneration [319] as well as
in progressive renal fibrosis [243]. Gal-3, indeed, appears to be a potent activator of fibroblasts in
the kidneys [320]. However, its absence is protective against renal myofibroblast accumulation and
activation [243]. Many studies, performed on mouse models of diabetic nephropathy and acute renal
failure, concordantly indicate that Gal-3 is upregulated in such conditions [215,243,319]. Interesting
results were obtained in studies performed also in humans with renal failure and especially with those
affected by diabetes. Gal3, in fact, was found to be upregulated in the glomeruli of diabetic patients
and the number of Gal-3 positive cells in the glomeruli correlated with the observed urinary protein
excretion [321], suggesting a potential prognostic role of Gal-3 in predicting a poor outcome of such
patients. In this regard, one of the most interesting observation regarding the correlation between
Gal-3 and kidney function comes from the LUdwigshafen RIsk and Cardiovascular health (LURIC)
study, based on data from 2578 patients [322] and from 4D studies based on data obtained from
1168 patients [323]. The analysis of Gal-3 plasma levels, measured in patients from these two large
prospective studies, demonstrated a significant association of Gal-3 levels with cardiovascular end
points, infections, and all-cause death in patients with impaired renal function [324]. The correlation
was observed during a period of follow-up extended to 10 years (LURIC study) or four years
(4D study) and the increase of Gal-3 levels was observed in parallel with the decrease in kidney
function, with a marked elevation in dialysis patients affected by T2DM. Based on such evidence, Gal-3
was proposed a novel treatment opportunity for renal disease. Kolatsi-Joannou et al. investigated
changes in the expression of Gal-3 in mice with acute kidney injury induced by folic acid, using
modified citrus pectin (MCP), a pectin derivative that can bind to the Gal-3 carbohydrate recognition
domain [325]. At two weeks of the recovery phase, MCP-treated mice demonstrated reduced Gal-3,
with decreased renal fibrosis, macrophages, pro-inflammatory cytokine expression, and apoptosis.
Their findings reveal that pharmacologic inhibition of Gal-3 with MCP was protective in experimental
nephropathy by modulating early proliferation and later, Gal-3 expression, apoptosis, and fibrosis.
Thus, MCP may be considered and proposed as a novel target to reduce long-term renal injuries,
attenuate renal fibrosis and preserve kidney function, possibly via the effect of Gal-3 on carbohydrate
binding-related functions [325]. A recent phase II study comparing treatment with another Gal-3
inhibitor, namely the GCS-100, and a placebo in patients with CKD stage 3b showed that GCS-100
significantly improved the eGFR [326]. Taken together, Gal-3 may be used to assess the prognosis,
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guide therapy, and potentially suggest specific anti-Gal-3 therapy. However, prospective studies are
needed to validate these hypotheses.
14. L
Liver Fibrosis
Liver fibrosis represents the final pathway of chronic damage to the liver, in conjunction with
the accumulation of extracellular matrix proteins [327]. Chronic inflammation with the formation of
scar tissue, loss of tissue architecture, and organ failure is a characteristic feature of this disease.
An increased in Gal-3 expression has been previously reported in fibrosis in different types of
tissues [170,308,328]. The main causes of liver fibrosis include chronic HCV infection, alcohol abuse,
and nonalcoholic steatohepatitis (NASH). Hepatic stellate cells (HSCs) are considered the main
collagen-producing cells in the liver. Gal-3 was found to play a critical role in the regulation of
HSC activation, both in vitro and in vivo [329]. In particular, the HSC activation to a myofibroblast
phenotype, a critical event in extracellular matrix deposition and in the development of cirrhosis,
is dependent on the upregulation of Gal-3 expression within liver cells, in the areas of fibrotic tissue
injury [327]. Based on such experimental and clinical evidence, a Phase 2b NASH-CX trial is ongoing
(ClinicalTrials.gov Identifier: NCT02462967) to treat NASH cirrhosis patients without esophageal
varices [330]. It is a randomized, double-blind, placebo-controlled clinical trial in patients with NASH
cirrhosis without varices and is aimed to target Gal-3 expression by means of an antagonist developed
by Galectin Therapeutics Inc. (Norcross, GA, USA) and named GR-MD-02. Preliminary results,
released by the company on 2 December 2017, indicate a positive trend in treated patients versus
placebo control patients, with an improvement in portal hypertension or liver biopsy. The results of
this trial could lead to a better treatment of such condition and to effective prevention of its progression
toward cirrhosis.
15. M
Mortality
Many different studies have reported that Gal-3 concentrations are associated with incident
HF and mortality in the general population and measurement of serum Gal-3 levels may be useful
in predicting mortality for all-cause and cardiovascular disease (CVD) [101–103,331]. Gal-3, in fact,
was a significant predictor of CVD mortality and of all-cause mortality in a large population study,
based on 1393 participants without CVD with a mean age of 70 years, who were followed up for
a mean of 11 years for the occurrence of coronary heart disease, CVD mortality, and all-cause
mortality [103]. The same results were reported by the Framingham Heart Study, based on 3353
participants in the Framingham Offspring Cohort (mean age 59 years, 53% women), in which Gal-3
was associated with risk of all-cause mortality [102] and by the Prevention of Renal and Vascular
ENd-stage Disease (PREVEND), based on 7968 subjects where Gal-3 levels independently predicted
all-cause mortality [101].
16. N
Non-Alcoholic Steatohepatitis (NASH)
Non-alcoholic steatohepatitis (NASH) is a condition in which fat builds up in the liver along
with inflammation, composed predominantly of lymphocytes and Kupffer cells, and liver damage,
in the absence of a history of alcoholism. It is more frequent in patients with obesity, metabolic
syndrome and T2DM and is the most common chronic liver disease, with a rapidly increasing
prevalence worldwide. The hallmarks of the disease are the presence, at histology, of steatosis,
lobular inflammation, hepatocellular ballooning and fibrosis, which typically begin in zone 3 and show
a characteristic perisinusoidal/pericellular (“chicken wire”) pattern [332]. A link between Gal-3 and
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hepatic fibrosis was established when mice that lack the Gal-3 gene were found to be resistant to liver
fibrosis induced by toxin administration [242]. Such observations are in agreement with studies in other
organs and systems regarding the role of Gal-3 in activating a variety of profibrotic factors, promoting
fibroblast proliferation and transformation, and mediating collagen production [333]. The effects
of Gal-3 knockout on NASH are rather controversial. It has been demonstrated that such mice are
resistant to fat accumulation, inflammation and fibrosis when fed a high-fat diet [334]. However, other
groups have demonstrated that Gal-3 null mice show an increased propensity to develop NASH [335].
An attempt to explain such discrepancy was recently given [336]. According to this study, Gal-3 null
animals are more prone to develop greater liver steatosis but there is decreased inflammation, liver cell
injury and fibrosis. Since Gal-3 appears to be a critical regulator of liver fibrosis attempts have been
made to inhibit its activity by means of a specific inhibitor, named GR-MB-02, in mice [337], in rats [338]
and in humans [339]. In particular, the human study was a sequential dose-ranging, placebo controlled,
double-blinded study and was undertaken to evaluate the safety, pharmacokinetics profiles and to
evaluate changes in potential serum biomarkers and liver stiffness as assessed by FibroScan in subjects
having NASH with bridging fibrosis. GR-MD-02 proved to be safe and well tolerated with evidence
of a pharmacodynamic effect. Such results constitute the basis for a Phase 2 development program
of treatment with GR-MD-02 in advanced fibrosis due to NASH. At the present time, the smaller
four-month long phase 2a trial, involving a small set of 30 NASH patients with advanced fibrosis
(NASH-FX) at a single site, indicate that the results missed the primary goal and a few secondary
endpoints [340], but additional positive results are expected from the larger in-progress phase 2b
clinical trial (NASH-FX) [341].
17. O
Obesity
Obesity is a common risk factor for metabolic syndrome, a group of several diseases
that include insulin resistance, hypertension, glucose intolerance and toxicity, hepatic steatosis,
atherogenic dyslipidemia, and T2DM [342]. Obesity correlates with chronic, low-grade inflammation,
which appears to be necessary for obesity-associated insulin resistance and the subsequent
development of T2DM [343]. During the development of obesity, macrophages permeate white
adipose tissue and, together with adipocytes, secrete various pro-inflammatory cytokines and
chemokines [344,345]. In obese individuals the visceral adipose tissue is infiltrated by macrophages
that cooperate in generating and sustaining the inflammatory responses [346]. Gal-3 is expressed in
all types of macrophages that permeate white adipose tissue and it is an important regulator of both
polarization and activity, thus mediating both pro-inflammatory and anti-inflammatory effects in such
cells [347,348]. Experimental evidence, using Gal-3−/− mice indicate that in vivo Gal-3 administration
causes glucose intolerance and insulin resistance whereas in vitro treatment with selective small
molecule Gal-3 inhibitors can directly induce decreased insulin sensitivity in myocytes, hepatocytes,
and adipocytes [349]. Such experiments suggest a possible interesting link between inflammation and
decreased insulin sensitivity.
18. P
18.1. Pneumonia
The Gram-positive bacterium Streptococcus pneumoniae is the most common cause of
community-acquired pneumonia, still responsible of a high mortality rate, especially in children
and in developing Countries [350]. In the lung, resident alveolar macrophages are the first line of
cellular defense and play a phagocytic role during the early stages of infection. Gal-3 is abundantly
expressed and secreted by macrophages [298] and clearance of apoptotic neutrophils by macrophages is
a key step in the resolution of inflammation. Using an in vivo pneumonia mouse model in which Gal-3
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was knocked out, it has been demonstrated that Gal-3 is involved in the recruitment of neutrophils
during lung infections with Streptococcus pneumoniae [301]. In addition, it was demonstrated that the
absence of Gal-3 is responsible for an inadequate host response to pneumococcal infection, resulting in
high mortality of the Gal-3-null mice [74,351,352]. In agreement with this observation, the exogenous
administration of Gal-3 was able to enhance phagocytosis of Streptococcus pneumoniae by both WT and
Gal-3−/− neutrophils [74,351]. In the same studies it has been demonstrated that administration of
exogenous Gal-3 had a direct antimicrobial, bacteriostatic effect on Streptococcus pneumoniae. Gal-3,
in fact, is able to inhibit in vitro growth of Streptococcus pneumoniae and to reduce the severity of
bacteremia and of the pneumonia in vivo. These very interesting and promising effects of Gal-3 may
have relevant clinical implications in the treatment of Pneumococcal pneumonia in humans but needs to
be further investigated.
18.2. Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a heterogeneous group of diseases. It includes the
idiopathic pulmonary hypertension characterized by a persistent increase in pulmonary arterial
resistance often related to small pulmonary arterial vessel remodeling and endothelial metabolic
alteration with consequent deterioration of lung and heart functions. During PAH increase of
pulmonary pressure is determined by microvascular inflammation, endothelial dysfunction, activation
of vascular smooth muscle cells and vascular thrombosis [353]. In this context, Gal-3 is able to
modulate fibroblast and endothelial behavior acting on fibroblast and vascular endothelial growth
factors [354]. Currently, there are few and contrasting studies addressing the precise role of Gal-3
in PAH development and progression. This confusion may be due to the different PAH patient
characteristics like the presence of comorbidities or diseases secondary complicated by PAH like
connective tissue diseases, respiratory or hearth diseases. Song et al. reported in 2016 that Gal-3
plasma levels are decreased in patients with PAH in comparison with healthy controls [355]. Moreover,
Gal-3 mRNA was down-regulated in the pulmonary vessels in pulmonary hypertensive rats [355].
Contrarily, elevated level of Gal-3 has been reported in PAH independently to etiology and associated
with severity of PAH [356,357]. Gal-3 plasma levels are correlated with right ventricle dysfunction [358]
and with extracellular matrix markers [356,357]. Gal-3 seems to play a key role in acute and chronic
inflammatory responses to endothelial injury, vascular remodeling and fibrosis in PAH [359]. The serial
measurement of Gal-3 serum levels was suggested as a useful marker to improve prediction and
progression of PAH [360]. A preclinical study demonstrated that Gal-3 might be also useful as a target
for the treatment of this condition. In fact, the treatment with Gal-3 inhibitors was able to counteract
lung and heart remodeling and fibrosis in a rat model of PAH [361].
18.3. Plaque Psoriasis
Gal-3 is abundantly expressed in the cytoplasm of normal keratinocytes, in hair follicles, sebaceous,
and sweat glands [87]. Moreover, Gal-3 is associated with keratinocyte differentiation and maturation [362].
Plaque psoriasis is one of the most prevalent autoimmune skin diseases. It is characterized by
the presence of well-demarcated red silvery scales on the skin surface. Gal-3 was expressed in a high
proportion of Langerhans cells from skin punch biopsies, obtained from lesional plaque-type psoriatic
skin [363]. In addition, a strong expression of Gal-3/Gal-3-reactive glycoligands was detected in
capillaries of psoriatic dermis [364].
However, the most relevant indication regarding the role of Gal-3 in psoriasis was obtained
unexpectedly during the exploratory phase 2 clinical trials on the use of GR-MD-02 in nonalcoholic
steatohepatitis (“NASH”) (ClinicalTrials.gov Identifier: NCT01899859). A side effect of the treatment
was, in fact, the evidence of long-term remission or significant improvements in disease activity of
psoriasis in patients treated with GR-MD-02. This finding suggested that blocking Gal-3 could be
effective in treating moderate to severe plaque psoriasis patients. That is why a new single-center,
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open-label phase 2a clinical trial was initiated to evaluate safety and efficacy of GR-MD-02 for treatment
of psoriasis (ClinicalTrials.gov Identifier: NCT02407041).
19. Q
Q Fever
The etiologic agent of Q-fever is a highly infectious human pathogen named Coxiella burnetii [365].
Coxiella burnetii is an obligate intracellular bacterium that inhabits mainly monocytes/macrophages.
It is known that galectins are recruited to injured membranes by their interactions with N-glycans
that are exposed to the cytoplasm when the membrane of a vesicle is pierced and, therefore,
are considered useful molecules to detect damage of intracellular membranous compartments.
In this regards, there is evidence derived from infection by two bacterial pathogens, namely the
Shigella flexneri, a rod-shaped, Gram-negative bacterium responsible for bacillary dysentary and
the Listeria monocytogenes, a rod-shaped Garm-positive bacterium that causes severe meningitis and
bacteriemia in immunocompromised hosts, that demonstrated that Gal-3 accumulates in structures
in close proximity to phagosomes containing bacterial pathogens and are useful to detect membrane
damage in bacteria’s vacuoles [366–368]. These bacteria share similar lifestyles in the sense that by
producing surface proteins they both lyse their phagosome and induce their own phagocytosis by host
cells [369]. In such bacteria it has been postulated that Gal-3 may function as a danger receptor for
membrane damages [366,367]. Similar to the behavior of these two pathogens also Coxiella burnetii was
found to transits through the endocytic pathway, which delivers the bacteria to the low pH environment
of a lysosome. Several members of the galectin family interact with the Coxiella burnetii containing
vacuole, at different times of infection. The role of the expression of Galectins, and in particular of
Gal-3 in the lysosomes of the infected cells appears to be crucial. It is believed that when lysosomes
are damaged they are marked with Gal-3 and, as a consequence, can be targeted to autophagy [370].
This study points to Gal-3 as a sensor of damage at the Coxiella burnetii limiting membrane and indicates
a possible role of Gal-3 in the mechanisms of autophagy during membrane repair.
20. R
20.1. Rheumatoid Arthritis
In contrast to Gal-1 that act as a negative regulator of autoimmunity in rheumatoid arthritis (RA),
Gal-3 promotes inflammation in RA. The role of Gal-3 as a pro-inflammatory mediator in RA is based
on several lines of evidence, both in animals and in humans [371].
20.1.1. Experimental Studies in Animals
Studies with collagen-induced arthritic (CIA) rats found increased Gal-3 secretion into the
plasma over time, which correlated with the disease progression, implicating that Gal-3 promotes
the development of experimental arthritis [372]. Recent studies with Gal-3-deficient mice further
confirmed the stimulating role of Gal-3 in arthritis [373]. The joint inflammation and bone erosion of
antigen-induced arthritis were markedly suppressed in Gal-3-deficient mice as compared with the
wild type mice. The reduced arthritis in Gal-3-deficient mice was accompanied by a decreased level of
antigen-specific IgG and pro-inflammatory cytokines, including TNFα, IL-6, and IL-17. Furthermore,
an exogenous supply of recombinant Gal-3 restored the reduced arthritis and cytokine production in
Gal-3-deficient mice [373]. This study provided the direct evidence that Gal-3 plays a crucial role in
the development of arthritis in animal models.
20.1.2. Clinical Studies in Humans
The role of Gal-3 in RA was also demonstrated in humans where Gal-3 was found to be increased
in the serum and synovial fluid of RA patients with long-standing disease, compared with osteoarthritis
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(OA) as well as in JIA patients [374–376]. The serum levels of Gal-3 were elevated in patients with
RA, JIA, Behçet’s disease, or systemic sclerosis [250,315,374,377]. Although the increased Gal-3 is
not specific for RA, the serum levels of Gal-3 were significantly associated with the C-reactive
protein (CRP) levels and the disease activity scores in patients with JIA, suggesting that Gal-3
may be utilized as a biomarker for the disease progression of JIA [315]. In addition, the LGALS3
gene allele (LGALS3 + 292C) is more prevalent in RA patients than in healthy controls, indicating
that genetic polymorphisms of Gal-3 may influence the susceptibility to RA [378]. In addition to
immune cells, fibroblast-like synoviocytes (FLS) in the synovium of RA patients also express Gal-3
at high levels [379–381]. While floating FLS only express low levels of Gal-3 [379], adhesion of
FLS to cartilage components through CD51/CD61 induces Gal-3 expression [375]. In RA patients,
about 39% of FLS are cartilage-adhering cells, which is four times more than in osteoarthritis (OA)
patients. The increased numbers of adhering FLS contribute to the elevated Gal-3 levels in the
RA synovium [375]. Moreover, Gal-3 can induce rheumatoid FLS to secret a set of pro-inflammatory
cytokines and chemokines including IL-6, granulocyte-macrophage colony-stimulating factor (GMCSF),
TNF, CXCL8, CCL2, CCL3, and CCL5 [381]. The induction of cytokines and chemokines by Gal-3
appears to involve different signaling pathways. The MAPK-ERK pathway was necessary for cyotokine
IL-6 production, while phosphatidylinositol 3-kinase (PI3K) was required for chemokine CCL5
induction [381]. These studies using human materials further suggest a promotional role of Gal-3 in the
pathogenesis of RA. In addition, Gal-3 mRNA and Gal-3 binding protein were highly expressed in RA
joints, particularly at the sites of cartilage and bone destruction [377]. Gal-3 was reported to contribute
to the activation of RA synovial fibroblasts [377] and to promote the production of pro-inflammatory
cytokines, such as interleukin-6 and tumor necrosis factor-α, in synovial fibroblasts [381,382]. For all
these reasons the Gal-3 serum level was proposed as a predictive marker of future RA [383]. According
to this study, the increase of serum levels of Gal-3 may help in discriminating between patients with
undifferentiated arthritis who subsequently developed RA and those with undifferentiated arthritis
who do not develop RA and in this sense it works better than other serological markers of cartilage
regeneration (such as the type IIA collagen N-terminal propeptide, PIIANP) or synovial swellings
(such as the hyaluronan, HYA). The therapeutic administration of lentiviral vectors encoding Gal-3
small hairpin RNA (shRNA), directly injected intra-articularly, into the ankle joints of rats with
collagen-induced arthritis, significantly ameliorates the disease activity [384]. This treatment, in fact,
reduced articular index scores, radiographic scores and histological scores and was accompanied with
decreased T-cell infiltrates and reduced microvessel density in the ankle joints. All these experimental
findings indicate that Gal-3 emerges not only as a key player in the pathogenesis of RA [385], but also
as a novel potential therapeutic target and implicate that down-regulation of Gal-3 may represent
novel a therapeutic strategy for RA.
21. S
21.1. Sepsis
Sepsis is a complex immune disorder with a high mortality rate of 20–50% that currently has
no therapeutic interventions [386]. There are few studies that suggested a possible role of Gal-3 in
inflammatory conditions, including endotoxemia and airway inflammation [71,387,388].
The relationship between Gal-3 and sepsis was recently studied using a murine inhalation model,
infected with Francisella novicida, a Gram negative bacterial pathogen, responsible for the development
of severe sepsis characterized by hyperinflammation, T cell depletion, and extensive cell death in
systemic organs. The measurement of both mRNA and protein levels of Gal-3 in lungs of mice
undergoing lethal pulmonary infection with such pathogen, indicated a significant increase in Gal-3
expression [386]. This increase was evident 3 days after lethal injection and was associated with
the appearance of other sepsis features, such as extensive cell death, hyperinflammatory response
and increased vascular injury. When the same treatment was given to Gal-3−/− mice, a significant
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reduction in levels of several vascular injury markers and of several inflammatory cytokines was
observed. In addition, Gal-3−/− mice showed significantly improved survival as compared to the
infected wild-type mice. These results indicate a strong immune-stimulatory role of Gal-3 during
pulmonary lethal infection and indicate that Gal-3 may represent a potential target for treatment of
sepsis, at least for that induced by Francisella novicida.
However, the situation may be different when other pathogens are involved. In fact, lipopolysaccharide
expressed on Escherichia coli has been shown to down-regulate Gal-3 expression [298,389].
Results similar to those observed with Francisella novicida were obtained also in the case of infection
with Streptococcus pneumonia. In this regard, it has been demonstrated that, after pneumococcal infection
of the lungs, Gal-3 accumulates in the alveolar space and this accumulation correlates with the onset
of neutrophil activation [301]. Infection of mice with the Gram-positive Streptococcus pneumoniae was
more severe when it was induced in Gal-3−/− mice, compared to wild-type, and Gal-3 released from
resident alveolar macrophages enhance their bacterial killing and phagocytic capability of neutrophils,
aiding pathogen clearance [351]. These data suggest that, conversely to what reported in sepsis induced
by Francisella novicida, Gal-3 may play a protective role against sepsis due to pulmonary infection by
Streptococcus pneumoniae. Recently, the hypothesis that Gal-3 could be useful as a marker to predict
mortality was tested in a group of 273 patients affected by sepsis and analyzed retrospectively [390].
Gal-3 was measured in association with other biomarkers, such as procalcitonin, presepsin, and soluble
ST2. Gal-3 showed the strongest prognostic value in predicting mortality in septic patients. Further
studies are required to elucidate the real diagnostic and prognostic usefulness of Gal-3 in septic patients
as well as its potential therapeutic use.
21.2. Systemic Sclerosis
Systemic sclerosis (SSc), also known as scleroderma, is a connective tissue disease characterized
by vasculopathy and progressive fibrosis of the skin and certain internal organs, due to activation
of fibroblasts and progressive accumulation of extracellular matrix molecules, eventually leading
to internal organ dysfunction [391]. Considering the known relevant role of Gal-3 in fibrosis [333]
it is obvious that it was analyzed in a disease such as SSc in which progressive fibrosis of the skin
and of visceral organs represents a major component of the disease. Serum Gal-3 levels were, in fact,
analyzed in patients affected by SSc in some studies. They were found to be significantly decreased
in early diffuse cutaneous SSc, compared with the control subjects, but showed increase during
the course of the disease [250]. In addition, in diffuse cutaneous SSc, a significant correlation was
reported between serum Gal-3 levels and the developmental process of skin sclerosis and of digital
ulcers [250]. In another study, serum Gal-3 levels were found to be higher in SSc patients than in
healthy controls [251]. In order to evaluate the possible associations between Gal-3 levels and patient
characteristics and to investigate its long-term prognostic value, a large population of 152 patients
that fulfilled the American College of Rheumatology criteria for SSc [392] was recently analyzed [255].
In multivariate Cox regression analyses and in a long-term follow-up (7.2 ± 2.3 years), Gal-3 was
an independent predictor both of the all-cause and of cardiovascular-related mortality, even after
adjustment for age, gender, BSA, creatinine and NT-proBNP levels. In particular, patients with elevated
serum Gal-3 levels (>10.25 ng/mL) showed a clear association with the signs of the advanced organ
sclerosis and with the laboratory parameters of inflammation. Gal-3 appears to be a reliable biomarker
to predict all-cause mortality in patients affected by SSc.
22. T
Target Therapy
Gal-3 is involved in the regulations of a myriad of cell activities. As a multifunctional protein
widely expressed by many types of human cells, it interacts with a range of different binding partners at
different locations. In addition, its overexpression in many different conditions and changes of its sub-
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and inter-cellular localization are commonly seen in various types of human diseases. Gal-3 research is
one of the fastest growing fields within medicine today and Gal-3 is becoming the most informative
new biomarker for our most serious health epidemics for which early detection is critical to successful
clinical prognosis. A growing body of evidence demonstrates, in fact, how Gal-3 is involved in
numerous degenerative processes within the body, most notably cancer proliferation/metastasis, heart
failure, atherosclerosis, diabetes, chronic inflammation, fibrosis and related organ failure. In addition,
Gal-3 was found to be a critical prognostic factor even in all-cause mortality. Therefore, it is not
surprising that Gal-3 represents an attractive molecule to be targeted for the development of new
strategies in the treatment of many different diseases [64]. The studies concerning the possibility to
inhibit Gal-3 function were driven by the experiments using Gal-3 null mice. Basically, two different
approaches were taken in developing drugs that target the Gal-3 molecule. One approach is based on
the use of modified disaccharides. One example of such compound is the TD139 (Galecto Biotech).
Another approach is to use naturally occurred large polysaccharides that contain galactose. Example of
such naturally occurred large polysaccharides are the modified citrus pectins (MCP), and in particular:
The GR-MD-02, belonging to the galacto-rhamnogalacturonate (GR) class and the GM-CT-01, belonging
to the galactomannan (GM) class, by Galectin therapeutics Inc. (Norcross, GA, USA) [393]. Recently,
another MCP compound, named PectaSol-C, was introduced and commercialized by EcoNugenics
(Santa Rosa, CA, USA). It was demonstrated to be able to reduce Gal-3 serum levels in vivo in both
mice [394] and humans [395].
The Gal-3 antagonist named GCS-100 is a MCP, capable of binding to and antagonizing Gal-3,
developed (La Jolla Pharmaceutical Company, San Diego, CA, USA) and utilized in a clinical
trial (ClinicalTrials.gov Identifier: NCT00776802) for the treatment of refractory diffuse large B-cell
lymphoma and refractory solid tumors [396]. The trial was discontinued in 2015 because of lack
of funding. The same drug was used in another interventional trial (ClinicalTrials.gov Identifier:
NCT01843790) for the treatment of patients with chronic kidney disease. Pectins are available as
various types of dietary fibers (e.g., fruit, vegetables, sugar beets). They constitute the fibers found in
the pith (the bitter, white stuff) in the peels of fruit, particularly rich in oranges, grapefruits, and lemons.
Pectins are commonly used as a thickening agent in jams and baked goods. Pectins have been identified
as Gal-3 inhibitors. Both pectins and MCP bind to the CRD of Gal-3 and neutralize its activity [397].
They were reported to be able to inhibit cancer growth and to be an effective anti-fibrotic agent in
mouse models [337,338,398–400].
A large numbers of clinical trials are now ongoing for many different clinical conditions. Currently,
there are 9 interventional clinical trials ongoing regarding the therapeutic use of Gal-3 inhibitors,
registered at the web site ClinicalTrials.gov, maintained by the National Library of Medicine (NLM) at
the National Institutes of Health (NIH) [401]. They include chronic inflammation and fibrosis affecting
the lung (ClinicalTrials.gov Identifier: NCT02257177) and the kidney (ClinicalTrials.gov Identifier:
NCT01717248 and NCT01843790), cirrhosis and portal hypertension (ClinicalTrials.gov Identifier:
NCT02462967), high blood pressure (ClinicalTrials.gov Identifier: NCT01960946), osteoarthritis
(ClinicalTrials.gov Identifier: NCT02800629), and combination immunotherapy for cancer, including
melanoma (ClinicalTrials.gov Identifier: NCT02117362 and NCT01723813), large B-cell lymphoma
(NCT00776802, withdrawn prior to enrollment for lack of funding). In addition, the occurrence of
serendipity has led to expand the potential clinical use of Gal-3 inhibitors also to skin diseases. In fact,
administration of GR-MD-02 to a patient enrolled in a Phase I NASH trial induced a remarkable
remission of psoriasis, indicating the potential importance of Gal-3 in such disease. Following this
observation, an open-label, phase 2a study was started in 2015 to evaluate safety and efficacy of GR-MD-02
for the treatment of psoriasis (ClinicalTrials.gov Identifier: NCT02407041). One could argue that a new
science is born, called “Pectin Science” or “Pectinology” [400]. The analysis of health promoting capacities
of Pectins is progressing fast and will provide interesting results in the near future.
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23. U
Urinary Tract Infections
Various galectins have been shown to bind a wide range of pathogens, such as Gram-positive bacteria
(e.g., Streptococcus pneumoniae), Gram-negative bacteria (e.g., Klebsiella pneumoniae, Neisseria meningitidis,
Neisseria gonorrhoeae, Haemophilus influenzae, Pseudomonas aeruginosa, Porphyromonas gingivalis,
Helicobacter pylori and Escherichia coli), enveloped viruses (Nipah and Hendra paramyxoviruses,
human immunodeficiency virus-1, HIV-1, and influenza virus A), retrovirus (human T-lymphotropic virus,
HTLV-1), hantavirus, fungi (Candida albicans) and parasites (Toxoplasma gondii, Leishmania major,
Schistosoma mansoni, Trypanosoma cruzi, and Trichomonas vaginalis) [259,282,402–410]. The specific role of
Gal-3 in urinary tract infections in humans was analyzed in case of viral and bacterial infections. Gal-3
serum levels were increased in patients with chronic viral infectious disease such as hepatitis C [411]
and HIV [412]. In particular, an elevated Gal-3 serum level was associated with unresponsiveness
to alpha-interferon treatment and a strong association was observed between viral load and Gal-3
expression in HIV-infected patients. Gal-3 was also investigated in case of urinary tract infection due
to bacterial infection. Gal-3 was found to play a crucial role in bacterial infections, and in particular in
infections due to Proteus mirabilis, a bacterium frequently detected in the urinary tract. Gal-3 influences
adhesion of such bacterium to the extracellular surface of the plasma membrane of different kidney
epithelial cell lines and its crucial role in Proteus mirabilis infection was demonstrated using specific
monoclonal antibodies directed against Gal-3 [413]. These studies indicate that Gal-3 plays a key role
of in renal pathology due to infections [414].
24. V
Venous Thrombosis
Gal-3 is associated with thrombogenesis and in particular, it is characterized by prothrombotic
and pro-inflammatory properties in the context of experimental venous thrombosis. Serum levels of
Gal-3 and of Gal-3 binding protein are elevated in the course of venous thrombosis in both mice and
humans [415]. Circulating Gal-3 is particularly elevated during the early phases of venous thrombosis
and its level correlates with the size of the thrombus. Gal-3 appears to be increased both locally, in the
thrombus and in the vein wall, and systemically, in blood-circulating elements, such as red blood
cells, with blood cells, platelets and microparticles. Therefore, Gal-3 may represent an ideal target for
therapies aimed to prevent venous thrombosis/pulmonary embolism [415].
25. W
25.1. Wound Healing
Many studies, performed in epithelium form different tissues, indicate that one of the best-known
functions of Gal-3 is to promote cell migration and wound re-epithelialization [416–419]. Impaired
wound healing and healing defects may affect the epithelium in many different organs systems,
including the skin, the gastrointestinal tract and the corneal epithelium [420–424]. In addition,
the damage of delayed re-epithelialization and the occurrence of persistent epithelial defects are
also observed in chronic wounds of the elderly, decubitus ulcers as well as in venous statis ulcers
of the skin. The major defect responsible for the failure to re-epithelialize in generally thought to
be the reduced ability of the epithelial cells to migrate across the wound healing bed more than a
defect in cell proliferation [425] and Gal-3 is able to modulate cell migration through its effects on cell
adhesion and its interactions with cell-matrix. For these reasons Gal-3 is considered a key player in the
re-epithelialization of wounds in many different tissues [426].
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25.1.1. Wound Healing in the Cornea
The effects of Gal-3 in the process of corneal re-epithelialization of wounds have been analyzed
using a Gal-3 null mouse model [416]. In such mouse model, the absence of Gal-3 impairs keratinocyte
migration and skin wound re-epithelialization. Using a mouse model in which corneas were injured
using both laser or alkali treatment it has been demonstrated that corneal epithelial wound closure rate
was significantly slower in Gal3−/− mice compared with wild-type mice [416]. Since the rate of corneal
epithelial cell proliferation is not altered in Gal3−/− mice, it is likely that the effect is due to impairment
in the cell migration process. To confirm this observation the mouse corneas were incubated in in
serum-free media, in the presence of different amounts of recombinant Gal-3 protein. Exogenous Gal-3
was able to stimulate the rate of wound closure in a concentration-dependent manner [416]. The same
effect was demonstrated the corneal epithelium of rats [427] and monkeys [428].
25.1.2. Wound Healing in the Skin
It is known that the EGF-stimulated EGFR-ERK signaling is essential for keratinocyte migration,
a crucial step for skin wound re-epithelialization [429–431]. The role of Gal-3 in skin wound
re-epithelialization was analyzed in a Gal-3−/− mouse model [432]. Keratinocyte migration is impaired
in Gal-3−/− mice. Gal-3 exerts this effect by regulating the intracellular trafficking of EGFR.
25.1.3. Wound Healing in the Intestinal Tract
Using the in vitro model of T84 human colonic adenocarcinoma cell line, it was demonstrated
that the Gal-3 promotes wound healing and that the cleavage of Gal-3 by Matrilysin-1 (MMP7) results
in the overall abrogation of such wound healing capacity [433]. Based on this observation it has
been hypothesized that cleavage of Gal-3 is one mechanism by which MMP7 inhibits wound healing.
The relevance of such finding and its possible clinical role in conditions such as intestinal ulcers and
chronic inflammatory bowel diseases still needs to be elucidated.
26. X
X Syndrome of the Heart
The X syndrome of the heart, also worded as cardiac syndrome X (CSX) and differing from
the other X syndrome of the metabolism, also known as metabolic syndrome X (MSX), refers to the
triad of typical effort angina, positive stress test and normal epicardial coronary angiogram [434].
It can be diagnosed in about 3–11% of patients undergoing coronary angiography because of typical
chest pain [435]. Follow-up studies of patients with CSX generally report good prognosis [436,437].
A systematic review of the literature shows that the CSX prognosis in terms of the overall cardiac
event rate is excellent, with a risk of myocardial infarction or cardiovascular death of 1.5% per five
years [438]. However, even if such patients have been considered to be a low-risk population the
occurrence of cardiovascular events in such patients is not infrequent, especially in women [439].
Many attempts have been made to find useful markers for identifying the CSX patients at high risk of
cardiovascular disease, and CRP, interleukin-6 and uric acid as well as the occurrence of perivascular
fibrosis, with higher carotid mean intima-media thickness, and apoptosis of endothelial cells in the
small blood vessels were found to be associated with such syndrome [440–442]. Serum levels of Gal-3
were measured in a cohort of 115 patients affected by CSX demonstrated. They were significantly
higher in the CSX patients in comparison with the healthy controls [443]. This preliminary study needs
to be validated in larger number of patients. However, it suggests that Gal-3 may play a key role in
the CSX and may represent a useful marker for identifying those CSX patients that are at high risk of
developing cardiovascular disease.
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27. Y
Yeast Infection-Candidiasis
Galectin family of lectins participates in the innate immune defense against pathogens [404]. Gal-3
was shown to have antimicrobial activity toward the pathogenic fungus Candida albicans [302]. Candida
species are the fourth leading cause of nosocomial bloodstream infections. They are responsible for
life threatening disease in immunocompromised individuals. Invasive candidiasis affects more than
250,000 people each year and leads to more than 50,000 deaths worldwide. In the United States
mortality due to systemic, invasive infections by Candida albicans can be as high as 40% even after
receiving antifungal therapy [444–446]. Vulvovaginal candidiasis affects 75% of women of childbearing
age [447]. It is interesting to note that Gal-3 is normally expressed by epithelia lining the body surfaces
that are exposed to Candida colonization, such as vulvar and oral mucosa, corneal, conjunctival and
intestinal epithelia [448–451]. Gal-3 appears to be present in the fungal granulomata, it binds to
Candida albicans in a carbohydrate-specific manner and it displays a direct fungicidal activity that may
be restricted to specific Candida species. This is the first observation regarding the direct antifungicidal
activity for a member of the galectin family of mammalian lectins. The ability to induce Candida
death is a unique function of Gal-3, because galectin-1 is not able to bind to any Candida species
examined. More recently Gal-3, secreted from neutrophils, was also demonstrated to be also active
against other non-albicans species, such as the Candida parapsilosis and the Candida albicans hyphae [452].
Gal-3, in fact, acts as a pro-inflammatory autocrine/paracrine signal in neutrophil phagocytosis. This
observation suggests that Gal-3 has a unique role in neutrophil response to Candida parapsilosis yeast
and Candida albicans hyphae distinct from Candida albicans yeast. In addition, Gal-3 plays an important
role in host recognition and response to candida infection, as demonstrated using a murine model of
disseminated candidiasis [453]. In such murine model, knockout of the Gal-3 gene (Gal-3−/− mice)
conferred susceptibility to Candida infection compared to wild type ones (Gal-3 WT-mice) [453]. When
infected with the less virulent specie, namely the Candida parapsilosis, Gal-3−/− mice had significantly
higher renal fungal burdens and abscess formation compared to Gal-3 WT-mice. This study suggests a
potential mechanism of neonatal susceptibility to these infections.
Additional informations will be obtained from studies aimed to analyze the gene polymorphisms
of candidate genes associated with yeast colonization [454,455]. In this regard, a new clinical trial
is now ongoing to analyze the innate immunity gene polymorphisms of the so-called “Candigene”.
In particular, aim of the study will be the genotyping of the following lectins: Mannose-binding lectin
(MBL), the Dectin-1 and the Gal-3 (ClinicalTrials.gov Identifier: NCT02888860).
The mechanism of Gal-3 secretion by the neutrophils and how it influences host defense was very
recently investigated [456]. According to this study Gal-3 deficiency ameliorates systemic candidiasis
by reducing fungal burden, renal pathology, and mortality. These studies indicate that blockade of Gal-3
in neutrophils may be a promising therapeutic strategy for systemic Candida infection. The inhibition
of Gal-3, obtained by knocking down the gene, by silencing its expression or by administration of
inhibitors such as the newly identified and TD139 molecule [457], patented by Galecto Biotech [458],
is able to inhibit neutrophil reactive oxygen species (ROS) production and enhance the ability of
neutrophils to kill when encountering “hard-to-kill” Candida.
28. Z
Zoster-Related Pain (Allodynia)
Herpes zoster (HZ) is caused by the reactivation of varicella zoster virus (VZV) after being latent in
the sensory ganglia [459,460] and is characterized by blistering skin eruption and neuropathic pain in
the affected dermatome [461]. It has been calculated that approximately 30% of population will suffer
of HZ during their lifetime [462]. Persistence of pain that lasts after the rash and blisters have healed,
a condition known as postherpetic neuralgia (PHN) or zoster-related pain, is considered as the most
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common and severe complication of HZ [463]. The sensory changes within the affected dermatome,
associated with both HZ and PHN, may induce reduced sensitivity of the skin as well as allodynia,
that is occurrence of pain due to stimulus which does not normally provoke pain [464]. Gal-3 is highly
expressed in peripheral nervous tissues of adult rodents, where is localized to cell bodies of sensory
neurons, axons and Schwann cells [465] and in the autonomic preganglionic neurons in the spinal
cord [466]. There is growing evidence suggesting that Gal-3 is involved in the process of Wallerian
degeneration distal to the injury and subsequent axonal regrowth and functional re-innervation [221].
To identify the genes involved in acute herpetic pain and analyze the role of Gal-3, a mouse model
(C57BL/6J) was subjected to transdermal Herpes simplex virus-1 (HSV-1) inoculation in the hind paw,
to produce Herpes zoster-like skin lesions and mechanical allodynia. In such mouse model Gal-3
expression levels as well as the global gene expression profiles of the dorsal cord, at the L4 to L6 levels,
were analyzed by GeneChip oligonucleotide expression arrays [236]. Gal-3 mRNA levels were slightly
induced on day 5 after inoculation, rapidly increased from day six to day eight, and then gradually
decreased. HSV-1 induced mechanical allodynia (day six after inoculation) caused a strong induction
of Gal-3 protein expression, analyzed by immunohistochemical methods, in the superficial part and
sparsely in the deep part of the lumbar dorsal horn on the HSV-1-inoculated side. To test whether
Gal-3 contributes to herpetic allodynia, the effects of deficiency in the Gal-3 gene were analyzed using
Gal-3−/− mice. In such mice, the onset (day five) and peak (around day seven) of HSV-1 induced
allodynia were similar to those of wild-type mice, but the intensity of the pain was significantly
reduced. Zoster-like skin lesions were not affected by the Gal-3 gene deficiency. Finally, the intrathecal
injection of rat and goat anti-Gal-3 antibodies significantly ameliorated HSV-1-induced allodynia.
Considering all these observations is not surprising that Gal-3 was considered as a key molecule in
the pathogenesis of neuropathic pain following peripheral nerve injury and tested for its possible
therapeutic use. In a rat model (Sprague–Dawley) in which neuroinflammation and neuropathic pain
were induced by L5 spinal nerve ligation (SNL), an increase in the mRNA and protein expression
levels of Gal-3 was observed in dorsal root ganglions [467]. Intrathecal administration of modified
citrus pectin (MCP), a Gal-3 inhibitor, was able to inhibit such effect, causing a reduction of Gal-3
expression in dorsal root ganglions. MCP treatment also inhibits SNL-induced Gal-3 expression in
primary rat microglia and decreases LPS-induced expression of pro-inflammatory mediators, such as
IL-1β, TNF-α and IL-6. Gal-3 inhibition resulted in a significant attenuation of neurophathic pain and
in a decreased mechanical and cold hypersensitivity. Gal-3 emerged as a new target for the treatment
and clinical management of peripheral nerve injury-induced neuropathic pain. No clinical studies
regarding the potential role of Gal-3 in postherpetic neuralgia in humans have been published yet.
29. Conclusions
This review represents an attempt to describe all the known clinical conditions in which a role of
Gal-3 was postulated or demonstrated. All the various clinical diseases and conditions, reported in this
review in alphabetical order, in which Gal-3 was analyzed and for which a specific clinical pathogenic,
diagnostic or prognostic role of Gal-3 was proposed are summarized in Table 1. However, this list should
not be considered completed yet. It is likely that many other diseases are still waiting to be analyzed and
added to it. It is impressive to realize how relevant is the clinical impact of all such studies on Gal-3 and
how fast was the introduction of clinical tests based on Gal-3 into clinical practice to be used as diagnostic
or prognostic biomarkers in many different clinical contexts. Even much impressive is the prompt use of
all the information regarding the pathogenic role of Gal-3 in severe diseases where few or no therapeutic
options are available to design new target treatments focused on Gal-3. Many different clinical trials
targeting Gal-3 molecule are still ongoing to treat severe neoplastic, fibrotic, metabolic and degenerative
disease and many pharmaceutical companies are investing money and efforts to develop and test drugs
targeting the Gal-3 molecule and acting as antagonist or agonist. The astonishing clinical history of this
extraordinary lectin and the new science called “Pectin Science” or “Pectinology” are just at the very earl
stages and the dawning of a new era with new exciting evolutions are expected soon.
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Table 1. Conditions and diseases, listed in alphabetical order, in which a possible role of Gal-3 was postulated in pathogenesis, diagnosis, prognosis, stratification for
therapy and in therapy.
Letter
Names Disease/Condition Possible Role in Pathogenesis Possible Role in Diagnosis/Prognosis
Possible Role in Patients
Stratification for Therapy Possible Role in Therapy
A Asthma Gal-3 positive patients are moreresponsive to omalizumab
Atherosclerosis Gal-3 is expressed in advancedatherosclerotic lesions
Atopic Dermatitis Gal-3 released by PMNs amplifiesIgE production
Gal-3 inhibitors used in a phase 2 controlled
trial for treatment of severe atopic dermatitis
B Blood test Blood assays (ELISA) to predict outcome ofacute and chronic heart failure
C Cancer Gal-3 controls oncogenesis, cancerprogression and metastasis
Diagnostic role in thyroid, prostate, and ovarian
cancers
Clinical trials using Gal-3 inhibitors for
melanoma and large B-cell lymphoma
Cerebral infarction Serum levels of Gal-3 are increased inischemic brain damage
Measurement of serum Gal-3 levels may help in
diagnosis of cerebral infarction
COPD Gal-3 levels measured in BAL are reduced inhealthy smokers
In patients with COPD serum Gal-3 levels may
predict right ventricular dysfunction and acute
exacerbation of COPD
D DegenerativeAortic Stenosis
Serum Gal-3 levels may be
useful in stratification for
therapy in elderly patients
affected by degenerative
aortic stenosis
Diabetes Mellitus
Conflicting results:
Gal-3 plays a rotective role;
Gal-3 is a risk factor for
vascular/renal/cardiac complications
E Endometriosis Gal-3 is overexpressed inendometriotic tissue
Enteric nervous system
Gal-3 is crucial mediator of the GI damage
observed after brain injuries, at the level of
enteric neuronal cells
Encephalitis
Gal-3 is involved in various types of
CNS inflammation and in particular in
viral encephalitis
F Fibrosis Gal-3 is key regulator of chronicinflammation and tissue fibrogenesis
Serum Gal-3 levels are increased in fibrosis
affecting the liver, the kidney, the lung, the heart,
the nervous system and in the systemic sclerosis.
In such conditions Gal-3 has been proposed as a
new prognostic factor
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Table 1. Cont.
Letter
Names Disease/Condition Possible Role in Pathogenesis Possible Role in Diagnosis/Prognosis
Possible Role in Patients
Stratification for Therapy Possible Role in Therapy
G Gastritis Gal-3 is upregulated in gastric epithelial cellsfollowing adhesion of Helicobacter pylori
Experimental evidence indicates that
administration of extracellular recombinant
Gal-3 (rGal-3) is able to inhibit the adhesion of
Helicobacter pylori to the gastric epithelial cells
H Heart Serum Gal-3 levels are associated with mortalityin patients with chronic heart failure
Gal-3 is useful as a marker for
stratification for therapy
(rosuvastatin and cardiac
resynchronization) in patient
with heart failure
HIV infection
Gal-3 is associated with early stages of HIV
infection and is involved in the host
response to HIV infection.
I Inflammation
Gal-3 is involved in many processes
during both acute and chronic
inflammatory response
Interstitial lung disease
Gal-3 is increased in the serum of patients
affected by IPF, and is associated with
decreased lung volumes and altered
gas exchange
A novel target therapy for IPF was proposed
using a Gal-3 inhibitor (TD139) formulated for
inhalation and a clinical trial process
was started
J Juvenile IdiopathicArthritis
Gal-3 serum levels are increased in
children affected by JIA and correlate with
disease activity
K Kidney Gal-3 serum levels are upregulated indiabetic nephropathy and acute renal failure
Experimental evidence indicates that
pharmacologic inhibition of Gal-3 with MCP is
protective toward nephropathy. Another Gal-3
inhibitor, the GCS-100, significantly improved
the eGFR in patients with CKD stage 3b.
L Liver fibrosis
Gal-3 plays a critical role in hepatic stellate
cells activation to a myofibroblast
phenotype, a critical event in extracellular
matrix deposition and in the development
of cirrhosis
A Gal-3 antagonist, named GR-MD-02, is
current on a phase 2 Clinical Trial to prevent
progression toward cirrhosis in patients
with NASH
M Mortality Gal-3 is associated with risk of coronary heartdisease, CVD mortality, and all-cause mortality
N Non-alcoholicsteatohepatitis (NASH)
Experimental evidence indicates that
mice lacking the Gal-3 gene are resistant to
liver fibrosis
The specific Gal-3 inhibitor, named GR-MB-02,
is on Phase 2 Clinical Trial for the treatment of
advanced fibrosis due to NASH
O Obesity
Gal-3 is expressed in all types of
macrophages that permeate white adipose
tissue and it is an important regulator of
their polarization and activity. Gal3 can bind
directly to the insulin receptor (IR) and
inhibit downstream IR signaling.
Experimental evidence in mice indicates that
inhibition of Gal-3 improves insulin sensitivity
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Table 1. Cont.
Letter
Names Disease/Condition Possible Role in Pathogenesis Possible Role in Diagnosis/Prognosis
Possible Role in Patients
Stratification for Therapy Possible Role in Therapy
P Pneumonia
Gal-3 is involved in the recruitment of
neutrophils during lung infections with
Streptococcus pneumoniae
Experimental evidence indicates that
exogenous administration of Gal-3 to mice has
a direct antimicrobial, bacteriostatic effect on
Streptococcus pneumonia
Pulmonary hypertension
Conflicting results:Gal-3 plasma levels are
decreased in patients with PAH;Gal-3
plasma levels are increased in PAH
independently to etiology and are are
associated with severity of PAH
Plaque Psoriasis
Gal-3 is expressed in a high proportion of
Langerhans cells from skin punch biopsies,
obtained from lesional plaque-type
psoriatic skin
An open-label phase 2a clinical trial is ongoing
using the Gal-3 antagonist GR-MD-02 for the
treatment of psoriasis
Q Q Fever Glactin-3 is a sensor of damage caused bythe Coxiella burnetii
R Rheumatoid Arthritis Gal-3 plays a key role as pro-inflammatorymediator in RA
Gal-3 serum level has been proposed as a
predictive marker of future RA
Experimental evidence indicates that
therapeutic intra-articularly administration of
lentiviral vectors encoding Gal-3 small hairpin
RNA (shRNA), in rats with collagen-induced
arthritis, significantly ameliorates
disease activity
S Sepsis
Serum Gal-3 levels may represent a useful
marker to predict mortality in patients affected
by sepsis
Experimental evidence indicates that Gal-3
may represent a potential target for treatment
of sepsis, at least for that induced by
Francisella novicida
Systemic Sclerosis
Serum Gal-3 levels correlate with the
developmental process of skin sclerosis and
of digital ulcers in diffuse cutaneous SSc
Gal-3 appears to be a reliable biomarker to
predict all-cause mortality in patients affected
by SSc
T Target therapy
Gal-3 is involved in numerous degenerative
processes within the body, including cancer
proliferation/metastasis, heart failure,
atherosclerosis, diabetes, chronic
inflammation, fibrosis and related
organ failure.
Numerous compounds that are able to inhibit
Gal-3 function have been proposed and are
currently in Clinical Trials for many different
diseases/conditions
U Urinary tract infections Gal-3 plays a role in urinary tract viral andbacterial infections in humans
V Venous Thrombosis
Serum levels of Gal-3 and of Gal-3 binding
protein are elevated in the course of venous
thrombosis
W Wound Healing
Gal-3 plays a key player in the
re-epithelialization of wounds in many
different tissues, including the cornea, the
skin and the GI tract
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Table 1. Cont.
Letter
Names Disease/Condition Possible Role in Pathogenesis Possible Role in Diagnosis/Prognosis
Possible Role in Patients
Stratification for Therapy Possible Role in Therapy
X X syndrome of the heart
Serum Gal-3 levels are significantly higher in
the CSX patients in comparison with the
healthy controls
Y Yeastinfection-Candidiasis
Gal-3 is present in the fungal granulomata, it
binds to Candida albicans in a
carbohydrate-specific manner and it
displays a direct fungicidal activity
Experimental evidence indicates that the
inhibition of Gal-3, obtained by knocking
down the gene, by silencing its expression or
by administration of the specific inhibitor
TD139 is able to inhibit neutrophil reactive
oxygen species (ROS) production and enhance
the ability of neutrophils to kill
Candida albicans
Z Zoster-related pain(allodynia)
Gal-3 is involved in the process of Wallerian
degeneration distal to the injury and
subsequent axonal regrowth and functional
re-innervation
Experimental evidence indicates that in mice
the intrathecal administration of the Gal-3
inhibitor modified citrus pectin (MCP) is able
to significantly attenuate neurophathic pain
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